93 results on '"Cammelli D"'
Search Results
2. Erratum: Management of adult-onset Still's disease with interleukin-1 inhibitors: Evidence- And consensus-based statements by a panel of Italian experts (Arthritis Res Ther (2019) 21:275 DOI: 10.1186/s13075-019-2021-9)
- Author
-
Colafrancesco, S., Manara, M., Bortoluzzi, A., Serban, T., Bianchi, G., Cantarini, L., Ciccia, F., Dagna, L., Govoni, M., Montecucco, C., Priori, R., Ravelli, A., Sfriso, P., Sinigaglia, L., Alivernini, S., Baldissera, E., Bartoloni, E., Berti, A., Bugatti, S., Camellino, D., Cammelli, D., Caporali, R., Caso, F., Cavallaro, E., Cavalli, G., Colaci, M., Costa, L., Di Scala, G., Emmi, G., Frassi, M., Gerli, R., Giacomelli, R., Gremese, E., Iannone, F., Lapadula, G., Leveghi, L., Lopalco, G., Manna, R., Marotto, D., Mathieu, A., Neri, R., Patisso, I., Piga, M., Punzi, L., Romano, M., Ruscitti, P., Salvarani, C., Scarpa, R., Scrivo, R., Talarico, R., Verrecchia, E., Viapiana, O., Vitale, A., AOSD Consensus Group: Alivernini S, Vitiello G., Baldissera, E, Bartoloni, E, Berti, A, Bugatti, S, Camellino, D, Cammelli, D, Caporali, R, Caso, F, Cavallaro, E, Cavalli, G, Colaci, M, Costa, L, di Scala, G, Emmi, G, and Frassi, M
- Published
- 2020
3. Erratum. management of adult-onset still's disease with interleukin-1 inhibitors. evidence- and consensus-based statements by a panel of Italian experts
- Author
-
Colafrancesco, S., Manara, M., Bortoluzzi, A., Serban, T., Bianchi, G., Cantarini, L., Ciccia, F., Dagna, L., Govoni, M., Montecucco, C., Priori, R., Ravelli, A., Sfriso, P., Sinigaglia, L., Alivernini, S., Baldissera, E., Bartoloni, E., Berti, A., Bugatti, S., Camellino, D., Cammelli, D., Caporali, R., Caso, F., Cavallaro, E., Cavalli, G., Colaci, M., Costa, L., Di Scala, G., Emmi, G., Frassi, M., Gerli, R., Giacomelli, R., Gremese, E., Iannone, F., Lapadula, G., Leveghi, L., Lopalco, G., Manna, R., Marotto, D., Mathieu, A., Neri, R., Patisso, I., Piga, M., Punzi, L., Romano, M., Ruscitti, P., Salvarani, C., Scarpa, R., Scrivo, R., Talarico, R., Verrecchia, E., Viapiana, O., Vitale, A., and Vitiello, G.
- Subjects
030203 arthritis & rheumatology ,0301 basic medicine ,medicine.medical_specialty ,Pediatrics ,Adult-onset Still's disease ,lcsh:Diseases of the musculoskeletal system ,business.industry ,Published Erratum ,MEDLINE ,Interleukin ,Rheumatology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Internal medicine ,medicine ,lcsh:RC925-935 ,business - Abstract
Following publication of the original article [1], it was brought to our attention that the AOSD Consensus Group was incorrectly tagged and therefore not searchable. The publishers apologize for this error.
- Published
- 2020
4. Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study
- Author
-
Quartuccio, L., Isola, M., Bruno, D., Treppo, E., Gigante, L., Angelotti, F., Capecchi, R., Vitiello, G., Cavallaro, E., Tavoni, A., Bosello, S. L., Cammelli, D., De Vita, S., Gremese, E., Bruno D., Gigante L., Bosello S. L. (ORCID:0000-0002-4837-447X), Gremese E. (ORCID:0000-0002-2248-1058), Quartuccio, L., Isola, M., Bruno, D., Treppo, E., Gigante, L., Angelotti, F., Capecchi, R., Vitiello, G., Cavallaro, E., Tavoni, A., Bosello, S. L., Cammelli, D., De Vita, S., Gremese, E., Bruno D., Gigante L., Bosello S. L. (ORCID:0000-0002-4837-447X), and Gremese E. (ORCID:0000-0002-2248-1058)
- Abstract
Objective: Glucocorticoids (GC) are associated with side effects in giant cell arteritis (GCA). Immunosuppressive therapies (ITs) have given conflicting results in GCA, regarding GC sparing effect. Primary endpoint is to evaluate whether very early introduction of ITs in GCA minimize the rate of GC-induced adverse events, in terms of infections, new onset systemic arterial hypertension, GC-induced diabetes and osteoporotic fractures. Methods: A multicenter retrospective case-control study included 165 patients. One group included 114 patients who were treated with at least one IT given at diagnosis or within 3 months from the start of GC. A second group included 51 GCA who received only GC or an IT more than 3 months later. Results: The most frequently used ITs were: methotrexate (138 patients), cyclophosphamide (48 patients) and tocilizumab (27 patients). No difference was observed as concerns the follow-up time between groups [48.5 (IQR 26–72) vs 40 (IQR 24–69), p = 0.3)]. The first group showed a significantly lower incidence of steroid-induced diabetes (8/114, 7% vs 12/51, 23.5%; p = 0.003) and no differences for the rate of infections (p = 0.64). The group was also exposed to lower doses of GC at first (p < 0.0001) and third (p < 0.0001, rank-sum test) month. Forty-four patients in the first group (38.6%) compared with 34 in the second one (66.7%) experienced at least one relapse (p = 0.001). Conclusion: Very early introduction of IT in GCA lowered the incidence of steroid-induced diabetes, possibly due to the lower doses of GC in the first three months. Relapse rate was even lower.
- Published
- 2020
5. Comparison of early vs. delayed anakinra treatment in patients with adult onset Still's disease and effect on clinical and laboratory outcomes
- Author
-
Vitale, A, Cavalli, G, Ruscitti, P, Sota, J, Colafrancesco, S, Priori, R, Valesini, G, Argolini, Lm, Baldissera, E, Bartoloni, E, Cammelli, D, Canestrari, G, Cavallaro, E, Massaro, Mg, Cipriani, P, De Marchi, G, De Vita, S, Emmi, G, Frassi, M, Gerli, R, Gremese, Elisa, Iannone, F, Fornaro, M, Paladini, A, Lopalco, G, Manna, Raffaele, Mathieu, A, Montecucco, C, Mosca, M, Piazza, I, Piga, M, Pontikaki, I, Romano, M, Rossi, S, Rossini, M, Silvestri, E, Stagnaro, C, Talarico, R, Frediani, B, Tincani, A, Viapiana, O, Vitiello, G, Galozzi, P, Sfriso, P, Gaggiano, C, Grosso, S, Rigante, Donato, Dagna, L, Giacomelli, R, Cantarini, L., Gremese E (ORCID:0000-0002-2248-1058), Manna R (ORCID:0000-0003-1560-3907), Rigante D (ORCID:0000-0001-7032-7779), Vitale, A, Cavalli, G, Ruscitti, P, Sota, J, Colafrancesco, S, Priori, R, Valesini, G, Argolini, Lm, Baldissera, E, Bartoloni, E, Cammelli, D, Canestrari, G, Cavallaro, E, Massaro, Mg, Cipriani, P, De Marchi, G, De Vita, S, Emmi, G, Frassi, M, Gerli, R, Gremese, Elisa, Iannone, F, Fornaro, M, Paladini, A, Lopalco, G, Manna, Raffaele, Mathieu, A, Montecucco, C, Mosca, M, Piazza, I, Piga, M, Pontikaki, I, Romano, M, Rossi, S, Rossini, M, Silvestri, E, Stagnaro, C, Talarico, R, Frediani, B, Tincani, A, Viapiana, O, Vitiello, G, Galozzi, P, Sfriso, P, Gaggiano, C, Grosso, S, Rigante, Donato, Dagna, L, Giacomelli, R, Cantarini, L., Gremese E (ORCID:0000-0002-2248-1058), Manna R (ORCID:0000-0003-1560-3907), and Rigante D (ORCID:0000-0001-7032-7779)
- Abstract
Background: Aim of this study was to search for any difference in the outcome of patients with adult onset Still's disease (AOSD) treated with anakinra (ANK) in relation with the interval between disease onset and the start of anti-interleukin(IL)-1 treatment and according with the different lines of ANK treatment. Patients and Methods: One hundred and forty-one AOSD patients treated with ANK have been retrospectively assessed. Statistically significant differences (p < 0.05) were analyzed in the frequency of ANK effectiveness, primary or secondary inefficacy to ANK and rate of resolution of clinical and laboratory AOSD manifestations after 3, 6, and 12 months since ANK treatment according with different lines of treatment and different times between AOSD onset and start of ANK. Results: No significant differences were identified in the ANK effectiveness and frequency of primary or secondary inefficacy for patients starting ANK within 6 months (p = 0.19, p = 0.14, and p = 0.81, respectively) or 12 months (p = 0.37, p = 0.23, and p = 0.81, respectively) since AOSD onset compared with patients starting ANK thereafter; no significant differences were identified in ANK effectiveness and primary or secondary inefficacy according with different lines of ANK treatment (p = 0.06, p = 0.19, and p = 0.13, respectively). Patients starting ANK within 6 and 12 months since AOSD onset showed a significantly quicker decrease of erythrocyte sedimentation rate and C-reactive protein than observed among patients undergoing ANK treatment after 6 and 12 months. The number of swollen joints at the 3 month follow-up visit was significantly lower among patients undergoing ANK within 6 months since AOSD onset (p = 0.01), while no significance was identified at the 6 and 12 month assessments (p = 0.23 and p = 0.45, respectively). At the 3 and 6 month visits, the number of swollen joints was significantly higher among patients previously treated with conventional and biological disease mo
- Published
- 2020
6. MRI of cerebral rheumatoid pachymeningitis: report of two cases with follow-up
- Author
-
Cellerini, M., Gabbrielli, S., Maddali Bongi, S., and Cammelli, D.
- Published
- 2001
- Full Text
- View/download PDF
7. FRI0216 STEROID SPARING EFFECT, LOWER INCIDENCE OF DISEASE RELAPSE AND DIABETES IN GIANT CELL ARTERITIS TREATED WITH IMMUNOSUPPRESSORS AB INITIO OR VERY EARLY: A MULTICENTER RETROSPECTIVE CASE-CONTROL STUDY
- Author
-
Quartuccio, L., primary, Isola, M., additional, Bruno, D., additional, Treppo, E., additional, Gigante, L., additional, Angelotti, F., additional, Capecchi, R., additional, Vitiello, G., additional, Cavallaro, E., additional, Tavoni, A., additional, Bosello, S. L., additional, Cammelli, D., additional, De Vita, S., additional, and Gremese, E., additional
- Published
- 2020
- Full Text
- View/download PDF
8. AB0601 RAPID AND SUSTAINED EFFICACY OF AN INDUCTION TREATMENT WITH A TRIPLE THERAPY INCLUDING HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS, METHOTREXATE AND GLUCOCORTICOIDS IN ANTI-3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE MYOPATHY
- Author
-
Treppo, E., primary, Infantino, M., additional, Benucci, M., additional, Ravagnani, V., additional, Palterer, B., additional, Grandis, M., additional, Fabris, M., additional, Tomietto, P., additional, Manfredi, M., additional, Sonaglia, A., additional, Giudizi, M. G., additional, Ligobbi, F., additional, Cammelli, D., additional, Parronchi, P., additional, De Vita, S., additional, and Quartuccio, L., additional
- Published
- 2020
- Full Text
- View/download PDF
9. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study
- Author
-
Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, Manna R, Cimaz R, Priori R, Talarico R, de Marchi G, Frassi M, Gallizzi R, Soriano A, Alessio M, Cammelli D, Maggio MC, Gentileschi S, Marcolongo R, La Torre F, Fabiani C, Colafrancesco S, Ricci F, Galozzi P, Viapiana O, Verrecchia E, Pardeo M, Cerrito L, Cavallaro E, Olivieri AN, Paolazzi G, Vitiello G, Maier A, Silvestri E, Stagnaro C, Valesini G, Mosca M, de Vita S, Tincani A, Lapadula G, Frediani B, De Benedetti F, Iannone F, Punzi L, Salvarani C, Galeazzi M, Angotti R, Messina M, Tosi GM, Rigante, Sota, J, Vitale, A, Insalaco, A, Sfriso, P, Lopalco, G, Emmi, G, Cattalini, M, Manna, R, Cimaz, R, Priori, R, Talarico, R, de Marchi, G, Frassi, M, Gallizzi, R, Soriano, A, Alessio, M, Cammelli, D, Maggio, Mc, Gentileschi, S, Marcolongo, R, La Torre, F, Fabiani, C, Colafrancesco, S, Ricci, F, Galozzi, P, Viapiana, O, Verrecchia, E, Pardeo, M, Cerrito, L, Cavallaro, E, Olivieri, An, Paolazzi, G, Vitiello, G, Maier, A, Silvestri, E, Stagnaro, C, Valesini, G, Mosca, M, de Vita, S, Tincani, A, Lapadula, G, Frediani, B, De Benedetti, F, Iannone, F, Punzi, L, Salvarani, C, Galeazzi, M, Angotti, R, Messina, M, Tosi, Gm, and Rigante
- Published
- 2018
10. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real life clinical practice: a nationwide multicenter retrospective observational study
- Author
-
Sota, J, Vitale, A, Insalaco, A, Sfriso, P, Lopalco, G, Emmi, G, Cattalini, M, Manna, R, Cimaz, R, Priori, R, Talarico, R, de Marchi, G, Frassi, M, Gallizzi, R, Soriano, A, Alessio, M, Cammelli, D, Maggio, Mc, Gentileschi, S, Marcolongo, R, La Torre, F, Fabiani, C, Colafrancesco, S, Ricci, F, Galozzi, P, Viapiana, O, Verrecchia, E, Pardeo, M, Cerrito, L, Cavallaro, E, Olivieri, An, Paolazzi, G, Vitiello, G, Maier, A, Silvestri, E, Stagnaro, C, Valesini, G, Mosca, M, de Vita, S, Tincani, A, Lapadula, G, Frediani, B, De Benedetti, F, Iannone, F, Punzi, L, Salvarani, C, Galeazzi, M, Angotti, R, Messina, M, Tosi, Gm, Rigante, D, Cantarini, L, 'Working Group' of Systemic Autoinflammatory Diseases of SIR (Italian Society of, Rheumatology)., Sota, J., Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., Manna, R., Cimaz, R., Priori, R., Talarico, R., de Marchi, G., Frassi, M., Gallizzi, R., Soriano, A., Alessio, M., Cammelli, D., Maggio, M. C., Gentileschi, S., Marcolongo, R., La Torre, F., Fabiani, C., Colafrancesco, S., Ricci, F., Galozzi, P., Viapiana, O., Verrecchia, E., Pardeo, M., Cerrito, L., Cavallaro, E., Olivieri, A. N., Paolazzi, G., Vitiello, G., Maier, A., Silvestri, E., Stagnaro, C., Valesini, G., Mosca, M., de Vita, S., Tincani, A., Lapadula, G., Frediani, B., De Benedetti, F., Iannone, F., Punzi, L., Salvarani, C., Galeazzi, M., Angotti, R., Messina, M., Tosi, G. M., Rigante, D., Cantarini, L., Sota, Jurgen, Vitale, Antonio, Insalaco, Antonella, Sfriso, Paolo, Lopalco, Giuseppe, Emmi, Giacomo, Cattalini, Marco, Manna, Raffaele, Cimaz, Rolando, Priori, Roberta, Talarico, Rosaria, de Marchi, Ginevra, Frassi, Micol, Gallizzi, Romina, Soriano, Alessandra, Alessio, Maria, Cammelli, Daniele, Maggio, Maria Cristina, Gentileschi, Stefano, Marcolongo, Renzo, La Torre, Francesco, Fabiani, Claudia, Colafrancesco, Serena, Ricci, Francesca, Galozzi, Paola, Viapiana, Ombretta, Verrecchia, Elena, Pardeo, Manuela, Cerrito, Lucia, Cavallaro, Elena, Olivieri, Alma Nunzia, Paolazzi, Giuseppe, Vitiello, Gianfranco, Maier, Armin, Silvestri, Elena, Stagnaro, Chiara, Valesini, Guido, Mosca, Marta, de Vita, Salvatore, Tincani, Angela, Lapadula, Giovanni, Frediani, Bruno, De Benedetti, Fabrizio, Iannone, Florenzo, Punzi, Leonardo, Salvarani, Carlo, Galeazzi, Mauro, Angotti, Rossella, Messina, Mario, Tosi, Gian Marco, Rigante, Donato, and Cantarini, Luca
- Subjects
Anakinra ,Autoinflammatory disorders ,Canakinumab ,Interleukin-1 ,Safety profile ,0301 basic medicine ,Male ,Settore MED/16 - REUMATOLOGIA ,0302 clinical medicine ,Retrospective Studie ,Rheumatology ,Child ,Antibodies, Monoclonal ,General Medicine ,Middle Aged ,Treatment Outcome ,Autoinflammation ,Female ,Cohort study ,medicine.drug ,Human ,Adult ,medicine.medical_specialty ,Adolescent ,Logistic Model ,Neutropenia ,Antibodies, Monoclonal, Humanized ,Autoimmune Disease ,Autoimmune Diseases ,03 medical and health sciences ,Young Adult ,Internal medicine ,Injection site reaction ,medicine ,Humans ,Anakinra, Autoinflammatory disorders, Canakinumab, Interleukin-1, Safety profile, Adolescent, Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Autoimmune Diseases, Child, Female, Humans, Interleukin 1 Receptor Antagonist Protein, Logistic Models, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Young Adult ,Adverse effect ,Retrospective Studies ,030203 arthritis & rheumatology ,business.industry ,Retrospective cohort study ,medicine.disease ,Interleukin 1 Receptor Antagonist Protein ,Logistic Models ,030104 developmental biology ,Autoinflammatory disorder ,Observational study ,business - Abstract
A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 patients/year. Safety concerns were more frequent among patients aged ≥ 65 years compared with patients < 16 years (p = 0.002). No differences were detected in the frequency of safety concerns between monotherapy and combination therapy with immunosuppressants (p = 0.055), but a significant difference was observed when injection site reactions were excluded from AE (p = 0.01). No differences were identified in relation to gender (p = 0.462), different lines of biologic therapy (p = 0.775), and different dosages (p = 0.70 ANA; p = 0.39 CAN). The overall drug retention rate was significantly different according to the occurrence of safety concerns (p value < 0.0001); distinguishing between ANA and CAN, significance was maintained only for ANA (p < 0.0001 ANA; p > 0.05 CAN). Treatment duration was the only variable associated with onset of AE (OR = 0.399 [C.I. 0.250–0.638], p = 0.0001). ANA and CAN have shown an excellent safety profile; the risk for AE and sAE tends to decrease over time from the start of IL-1 inhibition.
- Published
- 2018
11. Three dimensional vascular ultrasound imaging in medium and large vessel vasculitis: our experience
- Author
-
DE GREGORIO, MARIA GRAZIA, Cammelli, D, Vitiello, G, Brkljacic, B, Matucci Cerinic, M, and Castellani, S.
- Subjects
Inflammation ,genetic structures ,Arteries / Aorta ,Vascular ,Ultrasound-Colour Doppler ,Diagnostic procedure ,3d ultrasound imaging of temporal arteritis - Abstract
Aims and objectives Methods and materials Results Conclusion Personal information References, Aims and objectives: Giant cell arteritis (GCA) is the most frequent systemic vasculitis in middle-age and elderly caucasian populations. Besides temporal arteries, the disease can mainly involve the subclavian and axillary arteries and the aortic arch. The diagnosis of...
- Published
- 2019
- Full Text
- View/download PDF
12. Anakinra drug retention rate and predictive factors of drug survival in systemic juvenile idiopathic arthritis and adult onset Still’s disease
- Author
-
Sota, J, Rigante, Donato, Ruscitti, P, Insalaco, A, Sfriso, P, de Vita, S, Cimaz, R, Lopalco, G, Emmi, G, La Torre, F, Fabiani, C, Olivieri, An, Cattalini, M, Cammelli, D, Gallizzi, R, Alessio, M, Manna, Raffaele, Viapiana, O, Frassi, M, Maier, A, Salvarani, C, Talarico, R, Priori, R, Maggio, Mc, Vitale, A, Giacomelli, R, and Cantarini L for the Working Group of Systemic AutoInflammatory Diseases of, S. I. R.
- Subjects
Anakinra ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Juvenile idiopathic arthritis - Published
- 2019
13. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course
- Author
-
Cavagna, L, Trallero-Araguás, E, Meloni, F, Cavazzana, I, Rojas-Serrano, J, Feist, E, Zanframundo, G, Morandi, V, Meyer, A, Pereira da Silva, J, Matos Costa, C, Molberg, O, Andersson, H, Codullo, V, Mosca, M, Barsotti, S, Neri, R, Scirè, C, Govoni, M, Furini, F, Lopez-Longo, F, Martinez-Barrio, J, Schneider, U, Lorenz, H, Doria, A, Ghirardello, A, Ortego-Centeno, N, Confalonieri, M, Tomietto, P, Pipitone, N, Rodriguez Cambron, A, Blázquez Cañamero, M, Voll, R, Wendel, S, Scarpato, S, Maurier, F, Limonta, M, Colombelli, P, Giannini, M, Geny, B, Arrigoni, E, Bravi, E, Migliorini, P, Mathieu, A, Piga, M, Drott, U, Delbrueck, C, Bauhammer, J, Cagnotto, G, Vancheri, C, Sambataro, G, De Langhe, E, Sainaghi, P, Monti, C, Gigli Berzolari, F, Romano, M, Bonella, F, Specker, C, Schwarting, A, Villa Blanco, I, Selmi, C, Ceribelli, A, Nuno, L, Mera-Varela, A, Perez Gomez, N, Fusaro, E, Parisi, S, Sinigaglia, L, Del Papa, N, Benucci, M, Cimmino, M, Riccieri, V, Conti, F, Sebastiani, G, Iuliano, A, Emmi, G, Cammelli, D, Sebastiani, M, Manfredi, A, Bachiller-Corral, J, Sifuentes Giraldo, W, Paolazzi, G, Saketkoo, L, Giorgi, R, Salaffi, F, Cifrian, J, Caporali, R, Locatelli, F, Marchioni, E, Pesci, A, Dei, G, Pozzi, M, Claudia, L, Distler, J, Knitza, J, Schett, G, Iannone, F, Fornaro, M, Franceschini, F, Quartuccio, L, Gerli, R, Bartoloni, E, Bellando Randone, S, Zampogna, G, Gonzalez Perez, M, Mejia, M, Vicente, E, Triantafyllias, K, Lopez-Mejias, R, Matucci-Cerinic, M, Selva-O'Callaghan, A, Castañeda, S, Montecucco, C, Gonzalez-Gay, M, Cavagna, Lorenzo, Trallero-Araguás, Ernesto, Meloni, Federica, Cavazzana, Ilaria, Rojas-Serrano, Jorge, Feist, Eugen, Zanframundo, Giovanni, Morandi, Valentina, Meyer, Alain, Pereira da Silva, Jose Antonio, Matos Costa, Carlo Jorge, Molberg, Oyvind, Andersson, Helena, Codullo, Veronica, Mosca, Marta, Barsotti, Simone, Neri, Rossella, Scirè, Carlo, Govoni, Marcello, Furini, Federica, Lopez-Longo, Francisco Javier, Martinez-Barrio, Julia, Schneider, Udo, Lorenz, Hanns-Martin, Doria, Andrea, Ghirardello, Anna, Ortego-Centeno, Norberto, Confalonieri, Marco, Tomietto, Paola, Pipitone, Nicolò, Rodriguez Cambron, Ana Belen, Blázquez Cañamero, María Ángeles, Voll, Reinhard Edmund, Wendel, Sarah, Scarpato, Salvatore, Maurier, Francois, Limonta, Massimiliano, Colombelli, Paolo, Giannini, Margherita, Geny, Bernard, Arrigoni, Eugenio, Bravi, Elena, Migliorini, Paola, Mathieu, Alessandro, Piga, Matteo, Drott, Ulrich, Delbrueck, Christiane, Bauhammer, Jutta, Cagnotto, Giovanni, Vancheri, Carlo, Sambataro, Gianluca, De Langhe, Ellen, Sainaghi, Pier Paolo, Monti, Cristina, Gigli Berzolari, Francesca, Romano, Mariaeva, Bonella, Francesco, Specker, Christof, Schwarting, Andreas, Villa Blanco, Ignacio, Selmi, Carlo, Ceribelli, Angela, Nuno, Laura, Mera-Varela, Antonio, Perez Gomez, Nair, Fusaro, Enrico, Parisi, Simone, Sinigaglia, Luigi, Del Papa, Nicoletta, Benucci, Maurizio, Cimmino, Marco Amedeo, Riccieri, Valeria, Conti, Fabrizio, Sebastiani, Gian Domenico, Iuliano, Annamaria, Emmi, Giacomo, Cammelli, Daniele, Sebastiani, Marco, Manfredi, Andreina, Bachiller-Corral, Javier, Sifuentes Giraldo, Walter Alberto, Paolazzi, Giuseppe, Saketkoo, Lesley Ann, Giorgi, Roberto, Salaffi, Fausto, Cifrian, Jose, Caporali, Roberto, Locatelli, Francesco, Marchioni, Enrico, Pesci, Alberto, Dei, Giulia, Pozzi, Maria Rosa, Claudia, Lomater, Distler, Jorg, Knitza, Johannes, Schett, George, Iannone, Florenzo, Fornaro, Marco, Franceschini, Franco, Quartuccio, Luca, Gerli, Roberto, Bartoloni, Elena, Bellando Randone, Silvia, Zampogna, Giuseppe, Gonzalez Perez, Montserrat I, Mejia, Mayra, Vicente, Esther, Triantafyllias, Konstantinos, Lopez-Mejias, Raquel, Matucci-Cerinic, Marco, Selva-O'Callaghan, Albert, Castañeda, Santos, Montecucco, Carlomaurizio, Gonzalez-Gay, Miguel Angel, Cavagna, L, Trallero-Araguás, E, Meloni, F, Cavazzana, I, Rojas-Serrano, J, Feist, E, Zanframundo, G, Morandi, V, Meyer, A, Pereira da Silva, J, Matos Costa, C, Molberg, O, Andersson, H, Codullo, V, Mosca, M, Barsotti, S, Neri, R, Scirè, C, Govoni, M, Furini, F, Lopez-Longo, F, Martinez-Barrio, J, Schneider, U, Lorenz, H, Doria, A, Ghirardello, A, Ortego-Centeno, N, Confalonieri, M, Tomietto, P, Pipitone, N, Rodriguez Cambron, A, Blázquez Cañamero, M, Voll, R, Wendel, S, Scarpato, S, Maurier, F, Limonta, M, Colombelli, P, Giannini, M, Geny, B, Arrigoni, E, Bravi, E, Migliorini, P, Mathieu, A, Piga, M, Drott, U, Delbrueck, C, Bauhammer, J, Cagnotto, G, Vancheri, C, Sambataro, G, De Langhe, E, Sainaghi, P, Monti, C, Gigli Berzolari, F, Romano, M, Bonella, F, Specker, C, Schwarting, A, Villa Blanco, I, Selmi, C, Ceribelli, A, Nuno, L, Mera-Varela, A, Perez Gomez, N, Fusaro, E, Parisi, S, Sinigaglia, L, Del Papa, N, Benucci, M, Cimmino, M, Riccieri, V, Conti, F, Sebastiani, G, Iuliano, A, Emmi, G, Cammelli, D, Sebastiani, M, Manfredi, A, Bachiller-Corral, J, Sifuentes Giraldo, W, Paolazzi, G, Saketkoo, L, Giorgi, R, Salaffi, F, Cifrian, J, Caporali, R, Locatelli, F, Marchioni, E, Pesci, A, Dei, G, Pozzi, M, Claudia, L, Distler, J, Knitza, J, Schett, G, Iannone, F, Fornaro, M, Franceschini, F, Quartuccio, L, Gerli, R, Bartoloni, E, Bellando Randone, S, Zampogna, G, Gonzalez Perez, M, Mejia, M, Vicente, E, Triantafyllias, K, Lopez-Mejias, R, Matucci-Cerinic, M, Selva-O'Callaghan, A, Castañeda, S, Montecucco, C, Gonzalez-Gay, M, Cavagna, Lorenzo, Trallero-Araguás, Ernesto, Meloni, Federica, Cavazzana, Ilaria, Rojas-Serrano, Jorge, Feist, Eugen, Zanframundo, Giovanni, Morandi, Valentina, Meyer, Alain, Pereira da Silva, Jose Antonio, Matos Costa, Carlo Jorge, Molberg, Oyvind, Andersson, Helena, Codullo, Veronica, Mosca, Marta, Barsotti, Simone, Neri, Rossella, Scirè, Carlo, Govoni, Marcello, Furini, Federica, Lopez-Longo, Francisco Javier, Martinez-Barrio, Julia, Schneider, Udo, Lorenz, Hanns-Martin, Doria, Andrea, Ghirardello, Anna, Ortego-Centeno, Norberto, Confalonieri, Marco, Tomietto, Paola, Pipitone, Nicolò, Rodriguez Cambron, Ana Belen, Blázquez Cañamero, María Ángeles, Voll, Reinhard Edmund, Wendel, Sarah, Scarpato, Salvatore, Maurier, Francois, Limonta, Massimiliano, Colombelli, Paolo, Giannini, Margherita, Geny, Bernard, Arrigoni, Eugenio, Bravi, Elena, Migliorini, Paola, Mathieu, Alessandro, Piga, Matteo, Drott, Ulrich, Delbrueck, Christiane, Bauhammer, Jutta, Cagnotto, Giovanni, Vancheri, Carlo, Sambataro, Gianluca, De Langhe, Ellen, Sainaghi, Pier Paolo, Monti, Cristina, Gigli Berzolari, Francesca, Romano, Mariaeva, Bonella, Francesco, Specker, Christof, Schwarting, Andreas, Villa Blanco, Ignacio, Selmi, Carlo, Ceribelli, Angela, Nuno, Laura, Mera-Varela, Antonio, Perez Gomez, Nair, Fusaro, Enrico, Parisi, Simone, Sinigaglia, Luigi, Del Papa, Nicoletta, Benucci, Maurizio, Cimmino, Marco Amedeo, Riccieri, Valeria, Conti, Fabrizio, Sebastiani, Gian Domenico, Iuliano, Annamaria, Emmi, Giacomo, Cammelli, Daniele, Sebastiani, Marco, Manfredi, Andreina, Bachiller-Corral, Javier, Sifuentes Giraldo, Walter Alberto, Paolazzi, Giuseppe, Saketkoo, Lesley Ann, Giorgi, Roberto, Salaffi, Fausto, Cifrian, Jose, Caporali, Roberto, Locatelli, Francesco, Marchioni, Enrico, Pesci, Alberto, Dei, Giulia, Pozzi, Maria Rosa, Claudia, Lomater, Distler, Jorg, Knitza, Johannes, Schett, George, Iannone, Florenzo, Fornaro, Marco, Franceschini, Franco, Quartuccio, Luca, Gerli, Roberto, Bartoloni, Elena, Bellando Randone, Silvia, Zampogna, Giuseppe, Gonzalez Perez, Montserrat I, Mejia, Mayra, Vicente, Esther, Triantafyllias, Konstantinos, Lopez-Mejias, Raquel, Matucci-Cerinic, Marco, Selva-O'Callaghan, Albert, Castañeda, Santos, Montecucco, Carlomaurizio, and Gonzalez-Gay, Miguel Angel
- Abstract
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group's cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The "ex-novo" occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies' positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.
- Published
- 2019
14. Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response.
- Author
-
Vitale, A, Cavalli, G, Colafrancesco, S, Priori, R, Valesini, G, Argolini, Lm, Baldissera, E, Bartoloni, E, Cammelli, D, Canestrari, G, Sota, J, Cavallaro, E, Massaro, Maria Grazia, Ruscitti, P, Cipriani, P, De Marchi, G, De Vita, S, Emmi, G, Ferraccioli, Gianfranco, Frassi, M, Gerli, R, Gremese, Elisa, Iannone, F, Lapadula, G, Lopalco, G, Manna, Raffaele, Mathieu, A, Montecucco, C, Mosca, M, Piazza, I, Piga, M, Pontikaki, I, Romano, M, Rossi, S, Rossini, M, Silvestri, E, Stagnaro, C, Talarico, R, Tincani, A, Viapiana, O, Vitiello, G, Galozzi, P, Sfriso, P, Gaggiano, C, Rigante, Donato, Dagna, L, Giacomelli, R, Cantarini, L, Ferraccioli G (ORCID:0000-0001-6246-2428), Gremese E (ORCID:0000-0002-2248-1058), Manna R (ORCID:0000-0003-1560-3907), Rigante D (ORCID:0000-0001-7032-7779), Vitale, A, Cavalli, G, Colafrancesco, S, Priori, R, Valesini, G, Argolini, Lm, Baldissera, E, Bartoloni, E, Cammelli, D, Canestrari, G, Sota, J, Cavallaro, E, Massaro, Maria Grazia, Ruscitti, P, Cipriani, P, De Marchi, G, De Vita, S, Emmi, G, Ferraccioli, Gianfranco, Frassi, M, Gerli, R, Gremese, Elisa, Iannone, F, Lapadula, G, Lopalco, G, Manna, Raffaele, Mathieu, A, Montecucco, C, Mosca, M, Piazza, I, Piga, M, Pontikaki, I, Romano, M, Rossi, S, Rossini, M, Silvestri, E, Stagnaro, C, Talarico, R, Tincani, A, Viapiana, O, Vitiello, G, Galozzi, P, Sfriso, P, Gaggiano, C, Rigante, Donato, Dagna, L, Giacomelli, R, Cantarini, L, Ferraccioli G (ORCID:0000-0001-6246-2428), Gremese E (ORCID:0000-0002-2248-1058), Manna R (ORCID:0000-0003-1560-3907), and Rigante D (ORCID:0000-0001-7032-7779)
- Abstract
We have evaluated long-term retention rate of anakinra in adult onset Still disease and predictive factors for treatment response. The risk of losing anakinra efficacy increases along with the number of swollen joints at the start of therapy, while the typical skin rash is a negative predictor of anakinra withdrawal.
- Published
- 2019
15. THU0453 Efficacy of ab initio or very early introduction of immunosuppressive therapy in giant cell arteritis: a multicenter retrospective observational study
- Author
-
Quartuccio, L., primary, Cavallaro, E., additional, Angelotti, F., additional, Capecchi, R., additional, Vitiello, G., additional, Cammelli, D., additional, Tavoni, A., additional, and De Vita, S., additional
- Published
- 2018
- Full Text
- View/download PDF
16. First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome
- Author
-
Palterer, B., primary, Vitiello, G., additional, and Cammelli, D., additional
- Published
- 2017
- Full Text
- View/download PDF
17. P5201Diagnostic yield of color doppler ultrasonography in suspected giant cell arteritis: a clinical, sonographic and positron emission tomography retrospective analysis
- Author
-
Castellani, S., primary, Vitiello, G., additional, Selvaggio, S., additional, Cammelli, D., additional, Maggi, E., additional, and Di Mario, C., additional
- Published
- 2017
- Full Text
- View/download PDF
18. P569Diastolic dyssynchrony is associated with exercise intolerance in hypertensive patients with left ventricular hypertrophyP570Echocardiographic pattern of acute pulmonary embolism, analysis of consecutive 511 patientsP571Clinical significance of ventricular interdependence and left ventricular function in patients with pulmonary hypertension receiving specific vasodilator therapyP572Haemodynamic characteristics and ventricular mechanics in post-capillary and combined pre- and post-capillary pulmonary hypertensionP573Relationship between hematological response and echocardiographic features in patients with light chains systemic amyloidosisP574Myocardial changes in patients with anorexia nervosaP575Giant cell arteritis presenting as fever of unknown origin: role of clinical history, early positron emission tomography and ultrasound screeningP576Subclinical systolic dysfunction in systemic sclerosis is not influenced by standard rheumatologic therapy - a 4D echocardiographic studyP577Cardiac index correlates with the degree of hepatic steathosis in obese patients with obstructive sleep apneaP578Myocardial mechanics in top-level endurance athletes: a three-dimensional speckle tracking studyP579The athlete heart: what happens to myocardial deformation in physiological adaptation to sportsP580Association between left ventricle intrinsic function and urine protein-creatinine ratio in preeclampsia before and after deliveryP581Dilatation of the aorta in children with bicuspid aortic valveP582Cardiovascular functional abnormalities in patients with osteogenesis imperfectaP583Dobutamine stress test fast protocol: diagnostic accuracy and securityP584Prognostic value of non-positive exercise echocardiography in the patients submitted to percutaneous coronary interventionP585The use of myocardial strain imaging in the detection of coronary artery disease during stress echocardiographyP586Preserved O2 extraction exercise response in heart failure patients with chronotropic insufficiency: evidence for a central cardiac rather than peripheral oxygen uptake limitationP587Major determinant of O2 artero-venous difference at peak exercise in heart failure and healthy subjectsP588Stress echocardiography with contrast perfusion analysis for a more sensitive test for ischemic heart diseaseP589Assessment of mitral annular physiology in myxomatous mitral disease with 3D transesophageal echocardiography: comparison between early severe mitral regurgitation and decompensated groupP590Three-dimensional transesophageal echocardiographic assessment of the mitral valve geometry in patients with mild, moderate and severe chronic ischemic mitral regurgitationP591Left atrial appendage closure. Multimodality imaging in device size selectionP592Contributions of three-dimensional transesophageal echocardiography in the evaluation of aortic atherosclerotic plaquesP593Agitated blood-saline is superior to agitated air-saline for echocardiographic shunt studies
- Author
-
Jung, IH., primary, Kurnicka, K., primary, Enache, R., primary, Nagy, AI., primary, Martins, E., primary, Cereda, A., primary, Vitiello, G., primary, Magda, SL., primary, Styczynski, G., primary, Lo Iudice, F., primary, De Barros Viegas, H., primary, Shahab, F., primary, Trunina, I., primary, Mata Caballero, R., primary, Marques, A., primary, Shimoni, S., primary, Generati, G., primary, Bendix Salkvist Jorgensen, T., primary, Chen, TE., primary, Andrianova, A., primary, Fernandez-Golfin, C., primary, Corneli, MC., primary, Ali, M., primary, Seo, HS., additional, Kim, MJ., additional, Lichodziejewska, B., additional, Goliszek, S., additional, Dzikowska-Diduch, O., additional, Zdonczyk, O., additional, Kozlowska, M., additional, Kostrubiec, M., additional, Ciurzynski, M., additional, Palczewski, P., additional, Pruszczyk, P., additional, Popa, E., additional, Coman, IM., additional, Badea, R., additional, Platon, P., additional, Calin, A., additional, Beladan, CC., additional, Rosca, M., additional, Ginghina, C., additional, Popescu, BA., additional, Jurcut, R., additional, Venkateshvaran, AI., additional, Sola, SC., additional, Govind, SC., additional, Dash, PK., additional, Lund, L., additional, Manouras, AI., additional, Merkely, B., additional, Magne, J., additional, Aboyans, V., additional, Boulogne, C., additional, Lavergne, D., additional, Jaccard, A., additional, Mohty, D., additional, Casadei, F., additional, Spano, F., additional, Santambrogio, G., additional, Musca, F., additional, Belli, O., additional, De Chiara, B., additional, Bokor, D., additional, Giannattasio, C., additional, Corradi, E., additional, Colombo, CA., additional, Moreo, A., additional, Vicario, ML., additional, Castellani, S., additional, Cammelli, D., additional, Gallini, C., additional, Needleman, L., additional, Cruz, BK., additional, Maggi, E., additional, Marchionni, N., additional, Bratu, VD., additional, Mincu, RI., additional, Mihai, CM., additional, Gherghe, AM., additional, Florescu, M., additional, Cinteza, M., additional, Vinereanu, D., additional, Sobieraj, P., additional, Bielicki, P., additional, Krenke, R., additional, Szmigielski, CA., additional, Petitto, M., additional, Ferrone, M., additional, Esposito, R., additional, Vaccaro, A., additional, Buonauro, A., additional, Trimarco, B., additional, Galderisi, M., additional, Mendes, L., additional, Dores, H., additional, Melo, I., additional, Madeira, V., additional, Patinha, J., additional, Encarnacao, C., additional, Ferreia Santos, J., additional, Habib, F., additional, Soesanto, AM., additional, Sedyawan, J., additional, Abdurrazak, G., additional, Sharykin, A., additional, Popova, NE., additional, Karelina, EV., additional, Telezhnikova, ND., additional, Hernandez Jimenez, V., additional, Saavedra, J., additional, Molina, L., additional, Alberca, MT., additional, Gorriz, J., additional, L Pais, J., additional, Pavon, I., additional, Navea, C., additional, Alonso, JJ., additional, Sonia, S., additional, Cruz, I., additional, Joao, I., additional, Gomes, AC., additional, Caldeira, D., additional, Lopes, L., additional, Fazendas, P., additional, Pereira, H., additional, Edri, O., additional, Schneider, N., additional, Abaye, N., additional, Goerge, J., additional, Gandelman, G., additional, Bandera, F., additional, Alfonzetti, E., additional, Guazzi, M., additional, Villani, S., additional, Ferraro, O., additional, Ramberg, E., additional, Bhardwaj, P., additional, Nepper, ML., additional, Binko, TS., additional, Olausson, M., additional, Fink-Jensen, T., additional, Andersen, AM., additional, Roland, J., additional, Gleerup Fornitz, G., additional, Ong, K., additional, Suri, RM., additional, Enrique-Sarano, M., additional, Michelena, HI., additional, Burkhart, HM., additional, Gillespie, SM., additional, Cha, S., additional, Mankad, SV., additional, Saidova, MA., additional, Bolotova, MN., additional, Salido Tahoces, L., additional, Izurieta, C., additional, Villareal, G., additional, Esteban, A., additional, Urena Vacas, A., additional, Ayala, A., additional, Jimenez Nacher, JJ., additional, Hinojar Baydes, R., additional, Gonzalez Gomez, A., additional, Garcia, A., additional, Mestre, JL., additional, Hernandez Antolin, R., additional, Zamorano Gomez, JJ., additional, Perea, G., additional, Covelli, Y., additional, Henquin, R., additional, Ronderos, R., additional, Hepinstall, MJ., additional, Cassidy, CS., additional, Pellikka, PA., additional, Pislaru, SV., additional, and Kane, G., additional
- Published
- 2016
- Full Text
- View/download PDF
19. A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study
- Author
-
Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., Manna, Raffaele, Cimaz, R., Priori, R., Talarico, R., Gentileschi, Stefano, de Marchi, G., Frassi, M., Gallizzi, R., Soriano, A., Alessio, M., Cammelli, D., Maggio, M. C., Marcolongo, R., La Torre, F., Fabiani, C., Colafrancesco, S., Ricci, F., Galozzi, P., Viapiana, O., Verrecchia, E., Pardeo, M., Cerrito, Lucia, Cavallaro, E., Olivieri, A. N., Paolazzi, G., Vitiello, G., Maier, A., Silvestri, E., Stagnaro, C., Valesini, G., Mosca, M., de Vita, S., Tincani, A., Lapadula, G., Frediani, B., De Benedetti, F., Iannone, F., Punzi, L., Salvarani, C., Galeazzi, M., Rigante, Donato, Cantarini, L., Manna, Raffaele (ORCID:0000-0003-1560-3907), Gentileschi, S. (ORCID:0000-0001-9682-4706), Rigante, Donato (ORCID:0000-0001-7032-7779), Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., Manna, Raffaele, Cimaz, R., Priori, R., Talarico, R., Gentileschi, Stefano, de Marchi, G., Frassi, M., Gallizzi, R., Soriano, A., Alessio, M., Cammelli, D., Maggio, M. C., Marcolongo, R., La Torre, F., Fabiani, C., Colafrancesco, S., Ricci, F., Galozzi, P., Viapiana, O., Verrecchia, E., Pardeo, M., Cerrito, Lucia, Cavallaro, E., Olivieri, A. N., Paolazzi, G., Vitiello, G., Maier, A., Silvestri, E., Stagnaro, C., Valesini, G., Mosca, M., de Vita, S., Tincani, A., Lapadula, G., Frediani, B., De Benedetti, F., Iannone, F., Punzi, L., Salvarani, C., Galeazzi, M., Rigante, Donato, Cantarini, L., Manna, Raffaele (ORCID:0000-0003-1560-3907), Gentileschi, S. (ORCID:0000-0001-9682-4706), and Rigante, Donato (ORCID:0000-0001-7032-7779)
- Abstract
Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA was administered in 421 (80.04%) courses, CAN in 105 (19.96%). Sixty-two (32.1%) patients had been treated with both agents. IL-1 inhibitors were employed in 38 different indications (37 with ANA, 16 with CAN). Off-label use was more frequent for ANA than CAN (p < 0.0001). ANA was employed as first-line biologic approach in 323 (76.7%) cases, while CAN in 37 cases (35.2%). IL-1 inhibitors were associated with corticosteroids in 285 (54.18%) courses and disease modifying anti-rheumatic drugs (DMARDs) in 156 (29.65%). ANA dosage ranged from 30 to 200 mg/day (or 1.0-2.0 mg/kg/day) among adults and 2-4 mg/kg/day among children; regarding CAN, the most frequently used posologies were 150mg every 8 weeks, 150mg every 4 weeks and 150mg every 6 weeks. The frequency of failure was higher among patients treated with ANA at a dosage of 100 mg/day than those treated with 2 mg/kg/day (p = 0.03). Seventy-six patients (14.4%) reported an adverse event (AE) and 10 (1.9%) a severe AE. AEs occurred more frequently after the age of 65 compared to both children and patients aged between 16 and 65 (p = 0.003 and p = 0.03, respectively). Conclusions: IL-1 inhibitors are mostly used off-label, especially ANA, during adulthood. The high frequency of good clinical responses suggests that IL-1 inhibitors
- Published
- 2016
20. Anti-HMGCR antibody-associated necrotizing myopathy: diagnosis and treatment illustrated using a case report
- Author
-
Giudizi, MG, primary, Cammelli, D, additional, Vivarelli, E, additional, Biagiotti, R, additional, Ferraro, A, additional, Bentow, C, additional, Almerigogna, F, additional, Albesa, R, additional, and Mahler, M, additional
- Published
- 2016
- Full Text
- View/download PDF
21. BIOCHEMICAL MEASUREMENT OF LUNG CONNECTIVE TISSUE
- Author
-
Andreotti, L., primary, Cammelli, D., additional, Bussotti, A., additional, and Arcangeli, P., additional
- Published
- 1981
- Full Text
- View/download PDF
22. Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions.
- Author
-
Vultaggio, A., Petroni, G., Pratesi, S., Nencini, F., Cammelli, D., Milla, M., Prignano, F., Annese, V., Romagnani, S., Maggi, E., and Matucci, A.
- Subjects
INFLIXIMAB ,INFLAMMATION treatment ,ALLERGIES ,CELL proliferation ,DRUG development ,THERAPEUTIC use of immunoglobulins ,STATISTICAL correlation - Abstract
Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. This paper was addressed to detect IFX-specific T cells in treated patients with inflammatory diseases developing, or not, anti-drug antibodies (ADA) and to correlate the presence of specific T cells with the clinical outcomes of the treatment. A co-culture system of IFX-loaded dendritic cells and purified autologous CD4
+ T cells was used to detect memory T cells in 32 ADA+ and 39 ADA- IFX-treated patients and control groups. The cytokine profile of IFX-specific T cells was also studied in culture supernatants. IFX-specific cell proliferation was detected mainly in cells from ADA+ patients, irrespective of their different diseases. HR patients displayed higher T cell proliferation than non-responder and tolerant patients. A mixed [interferon (IFN)-γ, interleukin (IL)-13, IL-10] cytokine profile was shown in cells from ADA+ patients, while IL-10 was the most frequently detected cytokine in the supernatants of cultures from ADA- patients. Immunoglobulin (Ig)E+ ADA+ patients with previous HRs exhibited a more pronounced type 2 profile than IgE- ADA+ patients. This work provides evidence that IFX-specific circulating T cells are detectable mainly in ADA+ patients with HRs, regardless of their disease. The IFX-induced cytokine pattern partially correlates with the ADA isotype. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
23. AB0747 Churg-strauss syndrome complicated by heart inflammatory pseudotumor
- Author
-
Cammelli, D., primary and Rosselli, M., additional
- Published
- 2013
- Full Text
- View/download PDF
24. Connective tissue in aging lung.
- Author
-
Andreotti, Lupo, Bussotti, Alessandro, Cammelli, Daniele, Aiello, Elvira, Sampognaro, Salvatore, Andreotti, L, Bussotti, A, Cammelli, D, Aiello, E, and Sampognaro, S
- Published
- 1983
- Full Text
- View/download PDF
25. Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease
- Author
-
Jurgen Sota, Donato Rigante, Piero Ruscitti, Antonella Insalaco, Paolo Sfriso, Salvatore de Vita, Rolando Cimaz, Giuseppe Lopalco, Giacomo Emmi, Francesco La Torre, Claudia Fabiani, Alma Nunzia Olivieri, Marco Cattalini, Daniele Cammelli, Romina Gallizzi, Maria Alessio, Raffaele Manna, Ombretta Viapiana, Micol Frassi, Manuela Pardeo, Armin Maier, Carlo Salvarani, Rosaria Talarico, Marta Mosca, Serena Colafrancesco, Roberta Priori, Maria Cristina Maggio, Carla Gaggiano, Salvatore Grosso, Fabrizio De Benedetti, Antonio Vitale, Roberto Giacomelli, Luca Cantarini, Sota J., Rigante D., Ruscitti P., Insalaco A., Sfriso P., De Vita S., Cimaz R., Lopalco G., Emmi G., Torre F.L., Fabiani C., Olivieri A.N., Cattalini M., Cammelli D., Gallizzi R., Alessio M., Manna R., Viapiana O., Frassi M., Pardeo M., Maier A., Salvarani C., Talarico R., Mosca M., Colafrancesco S., Priori R., Maggio M.C., Gaggiano C., Grosso S., De Benedetti F., Vitale A., Giacomelli R., Cantarini L., Sota, J., Rigante, D., Ruscitti, P., Insalaco, A., Sfriso, P., De Vita, S., Cimaz, R., Lopalco, G., Emmi, G., Torre, F. L., Fabiani, C., Olivieri, A. N., Cattalini, M., Cammelli, D., Gallizzi, R., Alessio, M., Manna, R., Viapiana, O., Frassi, M., Pardeo, M., Maier, A., Salvarani, C., Talarico, R., Mosca, M., Colafrancesco, S., Priori, R., Maggio, M. C., Gaggiano, C., Grosso, S., De Benedetti, F., Vitale, A., Giacomelli, R., Cantarini, L., Sota, J, Rigante, D, Ruscitti, P, Insalaco, A, Sfriso, P, de Vita, S, Cimaz, R, Lopalco, G, Emmi, G, La Torre, F, Fabiani, C, Olivieri, An, Cattalini, M, Cammelli, D, Gallizzi, R, Alessio, M, Manna, R, Viapiana, O, Frassi, M, Pardeo, M, Maier, A, Salvarani, C, Talarico, R, Mosca, M, Colafrancesco, S, Priori, R, Maggio, Mc, Gaggiano, C, Grosso, S, De Benedetti, F, Vitale, A, and Giacomelli, R
- Subjects
0301 basic medicine ,Adult onset Still disease ,medicine.medical_specialty ,Arthritis ,Still Disease ,Anakinra ,Drug retention rate ,Innovative biotechnologies ,Interleukin 1-beta ,Personalized medicine ,Systemic juvenile idiopathic arthritis ,03 medical and health sciences ,0302 clinical medicine ,Settore MED/38 - Pediatria Generale E Specialistica ,anakinra, interleukin 1-beta, innovative biotechnologies, drug retention rate, systemic juvenile, idiopathic arthritis, adult onset Still disease, personalized medicine ,Internal medicine ,medicine ,Pharmacology (medical) ,Adverse effect ,Original Research ,Pharmacology ,business.industry ,Hazard ratio ,lcsh:RM1-950 ,medicine.disease ,Confidence interval ,Adult onset Still disease, Anakinra, Drug retention rate, Innovative biotechnologies, Interleukin 1-beta, Personalized medicine, Systemic juvenile idiopathic arthritis ,Discontinuation ,030104 developmental biology ,lcsh:Therapeutics. Pharmacology ,Innovative biotechnologie ,030220 oncology & carcinogenesis ,Cohort ,business ,medicine.drug - Abstract
Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Herein we report on the effectiveness of anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and Methods: This is a multicenter study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48-, and 60-month of follow-up was 74.3%, 62.9%, 49.4%, and 49.4%, respectively, without any significant differences between sJIA and AOSD patients (p = 0.164), and between patients treated in monotherapy compared with the subgroup coadministered with conventional diseasemodifying antirheumatic drugs (cDMARDs) (p = 0.473). On the other hand, a significant difference in DRR was found between biologic-naïve patients and those previously treated with biotechnologic drugs (p = 0.009), which persisted even after adjustment for pathology (p = 0.013). In the regression analysis, patients experiencing adverse events (AEs) {hazards ratio (HR) = 3.029 [confidence interval (CI) 1.750–5.242], p < 0.0001} and those previously treated with other biologic agents [HR = 1.818 (CI 1.007–3.282), p = 0.047] were associated with a higher HR of ANA discontinuation. The median treatment delay was significantly higher among patients discontinuing ANA (p < 0.0001). Significant corticosteroid-sparing (p = 0.033) and cDMARD-sparing effects (p < 0.0001) were also recorded. Less than one-third of our cohort developed AEs, and 85% were deemed mild in nature, with 70% of them involving the skin. Conclusions: Our findings display an overall excellent DRR of ANA on the long run for both sJIA and AOSD, that may be further optimized by closely monitoring patient’s safety issues and employing this IL-1 inhibitor as a first-line biologic as early as possible. Moreover, ANA allowed a significant drug-sparing effect and showed an overall good safety profile.
- Published
- 2019
26. Comparison of early vs. delayed anakinra treatment in patients with adult onset still's disease and effect on clinical and laboratory outcomes
- Author
-
Antonio Vitale, Giulio Cavalli, Piero Ruscitti, Jurgen Sota, Serena Colafrancesco, Roberta Priori, Guido Valesini, Lorenza Maria Argolini, Elena Baldissera, Elena Bartoloni, Daniele Cammelli, Giovanni Canestrari, Elena Cavallaro, Maria Grazia Massaro, Paola Cipriani, Ginevra De Marchi, Salvatore De Vita, Giacomo Emmi, Micol Frassi, Roberto Gerli, Elisa Gremese, Florenzo Iannone, Marco Fornaro, Anna Paladini, Giuseppe Lopalco, Raffaele Manna, Alessandro Mathieu, Carlomaurizio Montecucco, Marta Mosca, Ilaria Piazza, Matteo Piga, Irene Pontikaki, Micol Romano, Silvia Rossi, Maurizio Rossini, Elena Silvestri, Chiara Stagnaro, Rosaria Talarico, Bruno Frediani, Angela Tincani, Ombretta Viapiana, Gianfranco Vitiello, Paola Galozzi, Paolo Sfriso, Carla Gaggiano, Salvatore Grosso, Donato Rigante, Lorenzo Dagna, Roberto Giacomelli, Luca Cantarini, Vitale, A., Cavalli, G., Ruscitti, P., Sota, J., Colafrancesco, S., Priori, R., Valesini, G., Argolini, L. M., Baldissera, E., Bartoloni, E., Cammelli, D., Canestrari, G., Cavallaro, E., Massaro, M. G., Cipriani, P., De Marchi, G., De Vita, S., Emmi, G., Frassi, M., Gerli, R., Gremese, E., Iannone, F., Fornaro, M., Paladini, A., Lopalco, G., Manna, R., Mathieu, A., Montecucco, C., Mosca, M., Piazza, I., Piga, M., Pontikaki, I., Romano, M., Rossi, S., Rossini, M., Silvestri, E., Stagnaro, C., Talarico, R., Frediani, B., Tincani, A., Viapiana, O., Vitiello, G., Galozzi, P., Sfriso, P., Gaggiano, C., Grosso, S., Rigante, D., Dagna, L., Giacomelli, R., and Cantarini, L.
- Subjects
0301 basic medicine ,myalgia ,medicine.medical_specialty ,Settore MED/16 - REUMATOLOGIA ,adult onset Still's disease ,anakinra ,autoinflammatory diseases ,innovative biotechnologies ,interleukin-1 ,personalized medicine ,systemic onset juvenile idiopathic arthritis ,treat to target ,Etanercept ,03 medical and health sciences ,0302 clinical medicine ,systemic onset juvenile idiopathic arthriti ,autoinflammatory disease ,Internal medicine ,Still's disease ,medicine ,Original Research ,030203 arthritis & rheumatology ,Anakinra ,lcsh:R5-920 ,innovative biotechnologie ,medicine.diagnostic_test ,biology ,business.industry ,C-reactive protein ,Hydroxychloroquine ,General Medicine ,medicine.disease ,Systemic-onset juvenile idiopathic arthritis ,Infliximab ,030104 developmental biology ,Erythrocyte sedimentation rate ,biology.protein ,Medicine ,medicine.symptom ,business ,lcsh:Medicine (General) ,medicine.drug - Abstract
Background: Aim of this study was to search for any difference in the outcome of patients with adult onset Still's disease (AOSD) treated with anakinra (ANK) in relation with the interval between disease onset and the start of anti-interleukin(IL)-1 treatment and according with the different lines of ANK treatment. Patients and Methods: One hundred and forty-one AOSD patients treated with ANK have been retrospectively assessed. Statistically significant differences (p < 0.05) were analyzed in the frequency of ANK effectiveness, primary or secondary inefficacy to ANK and rate of resolution of clinical and laboratory AOSD manifestations after 3, 6, and 12 months since ANK treatment according with different lines of treatment and different times between AOSD onset and start of ANK. Results: No significant differences were identified in the ANK effectiveness and frequency of primary or secondary inefficacy for patients starting ANK within 6 months (p = 0.19, p = 0.14, and p = 0.81, respectively) or 12 months (p = 0.37, p = 0.23, and p = 0.81, respectively) since AOSD onset compared with patients starting ANK thereafter; no significant differences were identified in ANK effectiveness and primary or secondary inefficacy according with different lines of ANK treatment (p = 0.06, p = 0.19, and p = 0.13, respectively). Patients starting ANK within 6 and 12 months since AOSD onset showed a significantly quicker decrease of erythrocyte sedimentation rate and C-reactive protein than observed among patients undergoing ANK treatment after 6 and 12 months. The number of swollen joints at the 3 month follow-up visit was significantly lower among patients undergoing ANK within 6 months since AOSD onset (p = 0.01), while no significance was identified at the 6 and 12 month assessments (p = 0.23 and p = 0.45, respectively). At the 3 and 6 month visits, the number of swollen joints was significantly higher among patients previously treated with conventional and biological disease modifying anti-rheumatic drugs (DMARDs) compared with those formerly treated only with conventional DMARDs (p < 0.017). Conclusions: Clinical and therapeutic outcomes are substantially independent of how early ANK treatment is started in AOSD patients. However, a faster ANK effectiveness in controlling systemic inflammation and resolving articular manifestations may be observed in patients benefiting from IL-1 inhibition as soon as after disease onset.
- Published
- 2020
27. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course
- Author
-
Cavagna, Lorenzo, Trallero-Araguás, Ernesto, Meloni, Federica, Cavazzana, Ilaria, Rojas-Serrano, Jorge, Feist, Eugen, Zanframundo, Giovanni, Morandi, Valentina, Meyer, Alain, Pereira da Silva, Jose Antonio, Matos Costa, Carlo Jorge, Molberg, Oyvind, Andersson, Helena, Codullo, Veronica, Mosca, Marta, Barsotti, Simone, Neri, Rossella, Scirè, Carlo, Govoni, Marcello, Furini, Federica, Lopez-Longo, Francisco Javier, Martinez-Barrio, Julia, Schneider, Udo, Lorenz, Hanns-Martin, Doria, Andrea, Ghirardello, Anna, Ortego-Centeno, Norberto, Confalonieri, Marco, Tomietto, Paola, Pipitone, Nicolò, Rodriguez Cambron, Ana Belen, Blázquez Cañamero, María Ángeles, Voll, Reinhard Edmund, Wendel, Sarah, Scarpato, Salvatore, Maurier, Francois, Limonta, Massimiliano, Colombelli, Paolo, Giannini, Margherita, Geny, Bernard, Arrigoni, Eugenio, Bravi, Elena, Migliorini, Paola, Mathieu, Alessandro, Piga, Matteo, Drott, Ulrich, Delbrueck, Christiane, Bauhammer, Jutta, Cagnotto, Giovanni, Vancheri, Carlo, Sambataro, Gianluca, De Langhe, Ellen, Sainaghi, Pier Paolo, Monti, Cristina, Gigli Berzolari, Francesca, Romano, Mariaeva, Bonella, Francesco, Specker, Christof, Schwarting, Andreas, Villa Blanco, Ignacio, Selmi, Carlo, Ceribelli, Angela, Nuno, Laura, Mera-Varela, Antonio, Perez Gomez, Nair, Fusaro, Enrico, Parisi, Simone, Sinigaglia, Luigi, Del Papa, Nicoletta, Benucci, Maurizio, Cimmino, Marco Amedeo, Riccieri, Valeria, Conti, Fabrizio, Sebastiani, Gian Domenico, Iuliano, Annamaria, Emmi, Giacomo, Cammelli, Daniele, Sebastiani, Marco, Manfredi, Andreina, Bachiller-Corral, Javier, Sifuentes Giraldo, Walter Alberto, Paolazzi, Giuseppe, Saketkoo, Lesley Ann, Giorgi, Roberto, Salaffi, Fausto, Cifrián, José Manuel, Caporali, Roberto, Locatelli, Francesco, Marchioni, Enrico, Pesci, Alberto, Dei, Giulia, Pozzi, Maria Rosa, Claudia, Lomater, Distler, Jorg, Knitza, Johannes, Schett, George, Iannone, Florenzo, Fornaro, Marco, Franceschini, Franco, Quartuccio, Luca, Gerli, Roberto, Bartoloni, Elena, Bellando Randone, Silvia, Zampogna, Giuseppe, Gonzalez Perez, Montserrat I., Mejia, Mayra, Vicente, Esther, Triantafyllias, Konstantinos, Lopez-Mejias, Raquel, Matucci-Cerinic, Marco, Selva-O'Callaghan, Albert, Castañeda, Santos, Montecucco, Carlomaurizio, González-Gay, Miguel A., Universitat Autònoma de Barcelona, Universidad de Cantabria, Cavagna, L, Trallero-Araguás, E, Meloni, F, Cavazzana, I, Rojas-Serrano, J, Feist, E, Zanframundo, G, Morandi, V, Meyer, A, Pereira da Silva, J, Matos Costa, C, Molberg, O, Andersson, H, Codullo, V, Mosca, M, Barsotti, S, Neri, R, Scirè, C, Govoni, M, Furini, F, Lopez-Longo, F, Martinez-Barrio, J, Schneider, U, Lorenz, H, Doria, A, Ghirardello, A, Ortego-Centeno, N, Confalonieri, M, Tomietto, P, Pipitone, N, Rodriguez Cambron, A, Blázquez Cañamero, M, Voll, R, Wendel, S, Scarpato, S, Maurier, F, Limonta, M, Colombelli, P, Giannini, M, Geny, B, Arrigoni, E, Bravi, E, Migliorini, P, Mathieu, A, Piga, M, Drott, U, Delbrueck, C, Bauhammer, J, Cagnotto, G, Vancheri, C, Sambataro, G, De Langhe, E, Sainaghi, P, Monti, C, Gigli Berzolari, F, Romano, M, Bonella, F, Specker, C, Schwarting, A, Villa Blanco, I, Selmi, C, Ceribelli, A, Nuno, L, Mera-Varela, A, Perez Gomez, N, Fusaro, E, Parisi, S, Sinigaglia, L, Del Papa, N, Benucci, M, Cimmino, M, Riccieri, V, Conti, F, Sebastiani, G, Iuliano, A, Emmi, G, Cammelli, D, Sebastiani, M, Manfredi, A, Bachiller-Corral, J, Sifuentes Giraldo, W, Paolazzi, G, Saketkoo, L, Giorgi, R, Salaffi, F, Cifrian, J, Caporali, R, Locatelli, F, Marchioni, E, Pesci, A, Dei, G, Pozzi, M, Claudia, L, Distler, J, Knitza, J, Schett, G, Iannone, F, Fornaro, M, Franceschini, F, Quartuccio, L, Gerli, R, Bartoloni, E, Bellando Randone, S, Zampogna, G, Gonzalez Perez, M, Mejia, M, Vicente, E, Triantafyllias, K, Lopez-Mejias, R, Matucci-Cerinic, M, Selva-O'Callaghan, A, Castañeda, S, Montecucco, C, and Gonzalez-Gay, M
- Subjects
medicine.medical_specialty ,antisynthetase antibodies ,antisynthetase syndrome ,arthritis ,interstitial lung disease ,myositis ,Medizin ,Arthritis ,lcsh:Medicine ,Antisynthetase syndrome ,Interstitial lung disease ,Article ,NO ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,antisynthetase antibodies, antisynthetase syndrome, arthritis, interstitial lung disease, myositis ,ddc:610 ,Myositis ,030203 arthritis & rheumatology ,Antisynthetase antibodies ,biology ,business.industry ,lcsh:R ,Autoantibody ,General Medicine ,medicine.disease ,arthriti ,030228 respiratory system ,Time course ,Cohort ,biology.protein ,Antibody ,business ,antisynthetase antibodie - Abstract
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group's cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The "ex-novo" occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies' positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition. ispartof: JOURNAL OF CLINICAL MEDICINE vol:8 issue:11 ispartof: location:Switzerland status: published
- Published
- 2019
28. Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response
- Author
-
Antonio Vitale, Giulio Cavalli, Serena Colafrancesco, Roberta Priori, Guido Valesini, Lorenza Maria Argolini, Elena Baldissera, Elena Bartoloni, Daniele Cammelli, Giovanni Canestrari, Jurgen Sota, Elena Cavallaro, Maria Grazia Massaro, Piero Ruscitti, Paola Cipriani, Ginevra De Marchi, Salvatore De Vita, Giacomo Emmi, Gianfranco Ferraccioli, Micol Frassi, Roberto Gerli, Elisa Gremese, Florenzo Iannone, Giovanni Lapadula, Giuseppe Lopalco, Raffaele Manna, Alessandro Mathieu, Carlomaurizio Montecucco, Marta Mosca, Ilaria Piazza, Matteo Piga, Irene Pontikaki, Micol Romano, Silvia Rossi, Maurizio Rossini, Elena Silvestri, Chiara Stagnaro, Rosaria Talarico, Angela Tincani, Ombretta Viapiana, Gianfranco Vitiello, Paola Galozzi, Paolo Sfriso, Carla Gaggiano, Donato Rigante, Lorenzo Dagna, Roberto Giacomelli, Luca Cantarini, Vitale, A., Cavalli, G., Colafrancesco, S., Priori, R., Valesini, G., Argolini, L. M., Baldissera, E., Bartoloni, E., Cammelli, D., Canestrari, G., Sota, J., Cavallaro, E., Massaro, M. G., Ruscitti, P., Cipriani, P., De Marchi, G., De Vita, S., Emmi, G., Ferraccioli, G., Frassi, M., Gerli, R., Gremese, E., Iannone, F., Lapadula, G., Lopalco, G., Manna, R., Mathieu, A., Montecucco, C., Mosca, M., Piazza, I., Piga, M., Pontikaki, I., Romano, M., Rossi, S., Rossini, M., Silvestri, E., Stagnaro, C., Talarico, R., Tincani, A., Viapiana, O., Vitiello, G., Galozzi, P., Sfriso, P., Gaggiano, C., Rigante, D., Dagna, L., Giacomelli, R., and Cantarini, L.
- Subjects
musculoskeletal diseases ,0301 basic medicine ,Autoinflammatory disease ,medicine.medical_specialty ,Settore MED/16 - REUMATOLOGIA ,Canakinumab ,Autoinflammatory diseases ,Arthritis ,Disease ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Still's disease ,medicine ,Pharmacology (medical) ,Adverse effect ,Still disease ,Original Research ,Pharmacology ,Anakinra ,business.industry ,lcsh:RM1-950 ,Innovative biotechnologies ,medicine.disease ,Rash ,Personalized medicine ,Systemic-onset juvenile idiopathic arthritis ,lcsh:Therapeutics. Pharmacology ,030104 developmental biology ,Interleukin-1 ,Systemic onset juvenile idiopathic arthritis ,Innovative biotechnologie ,030220 oncology & carcinogenesis ,Concomitant ,Autoinflammation ,medicine.symptom ,business ,medicine.drug - Abstract
Background: Anakinra (ANA) is an effective treatment choice in patients with adult onset Still’s disease (AOSD). Variables affecting treatment survival include loss of efficacy or adverse events, but also the decision to discontinue treatment after long-term clinical remission. Objectives: Aims of this study were: (i) to assess the drug retention rate (DRR) of ANA during a long-term follow-up looking for any difference related to the line of biologic treatment, the concomitant use of conventional disease modifying anti-rheumatic drugs (cDMARDs) and the different type of AOSD (systemic versus chronic articular); (ii) to identify predictive factors of lack of efficacy, loss of efficacy, and ANA withdrawal owing to long-term remission. Methods: AOSD patients classified according with Yamaguchi criteria and treated with ANA were retrospectively enrolled in 18 Italian tertiary Centers. Demographic, laboratory, clinical and therapeutic data related to the start of ANA (baseline), the 3-month assessment and the last follow-up visit while on ANA treatment were retrospectively collected and statistically analyzed. Results: One hundred and forty-one AOSD patients (48 males, 93 females) treated with ANA for a mean period of 35.96 ± 36.05 months were enrolled. The overall DRR of ANA was 44.6 and 30.5% at the 60- and 120-month assessments, respectively, with no significant differences between: (i) biologic naïve patients and those previously treated with other biologics (log-rank p = 0.97); (ii) monotherapy and concomitant use of cDMARDs (log-rank p = 0.45); (iii) systemic and chronic articular types of AOSD (log-rank p = 0.67). No variables collected at baseline could predict primary inefficacy, while the number of swollen joints at baseline was significantly associated with secondary inefficacy (p = 0.01, OR = 1.194, C.I. 1.043–1.367). The typical AOSD skin rash was negatively related with ANA withdrawal owing to long-term remission (p = 0.03, OR = 0.224, C.I. 0.058–0.863). Conclusion: Long-term DRR of ANA has been found excellent and is not affected by different lines of biologic treatment, concomitant use of cDMARDs, or type of AOSD. The risk of losing ANA efficacy increases along with the number of swollen joints at the start of therapy, while the typical skin rash is a negative predictor of ANA withdrawal related to sustained remission.
- Published
- 2019
29. A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study
- Author
-
Fabrizio De Benedetti, Elena Cavallaro, Antonio Vitale, Elena Verrecchia, Alma Nunzia Olivieri, Maria Carla De Maggio, Leonardo Punzi, Giovanni Lapadula, Giuseppe Lopalco, Stefano Gentileschi, Lucia Cerrito, Florenzo Iannone, Marta Mosca, Paolo Sfriso, Giuseppe Paolazzi, Romina Gallizzi, Francesco La Torre, Gianfranco Vitiello, Serena Colafrancesco, Renzo Marcolongo, Chiara Stagnaro, Angela Tincani, Ginevra De Marchi, Carlo Salvarani, Raffaele Manna, Francesca Ricci, Ombretta Viapiana, Paola Galozzi, Mauro Galeazzi, Armin Maier, Rosaria Talarico, M Pardeo, Donato Rigante, Luca Cantarini, Salvatore De Vita, Rolando Cimaz, Maria Alessio, Antonella Insalaco, Claudia Fabiani, Giacomo Emmi, Alessandra Soriano, Micol Frassi, Marco Cattalini, Roberta Priori, Elena Silvestri, Bruno Frediani, Daniele Cammelli, Guido Valesini, Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., Manna, R., Cimaz, R., Priori, R., Talarico, R., Gentileschi, S., de Marchi, G., Frassi, M., Gallizzi, R., Soriano, A., Alessio, M., Cammelli, D., Maggio, M. C., Marcolongo, R., La Torre, F., Fabiani, C., Colafrancesco, S., Ricci, F., Galozzi, P., Viapiana, O., Verrecchia, E., Pardeo, M., Cerrito, L., Cavallaro, E., Olivieri, A. N., Paolazzi, G., Vitiello, G., Maier, A., Silvestri, E., Stagnaro, C., Valesini, G., Mosca, M., de Vita, S., Tincani, A., Lapadula, G., Frediani, B., De Benedetti, F., Iannone, F., Punzi, L., Salvarani, C., Galeazzi, M., Rigante, D., Cantarini, L., Maggio, M., and Olivieri, A.
- Subjects
medicine.medical_specialty ,autoinflammatory disorders, treatment, interleukin (IL)-1, anakinra, canakinumab ,Dose ,anakinra ,autoinflammatory disorders ,canakinumab ,interleukin (IL)-1 ,treatment ,030204 cardiovascular system & hematology ,Off-label use ,03 medical and health sciences ,Settore MED/38 - Pediatria Generale E Specialistica ,0302 clinical medicine ,Internal medicine ,medicine ,Pharmacology (medical) ,Interleukin-1 inhibitors ,Adverse effect ,Original Research ,030203 arthritis & rheumatology ,Pharmacology ,Anakinra ,business.industry ,lcsh:RM1-950 ,Autoinflammatory disorders ,Canakinumab ,Interleukin (IL)-1 ,Treatment ,Interleukin ,Retrospective cohort study ,Surgery ,lcsh:Therapeutics. Pharmacology ,Autoinflammatory disorder ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Antirheumatic drugs ,business ,medicine.drug - Abstract
Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA was administered in 421 (80.04%) courses, CAN in 105 (19.96%). Sixty-two (32.1%) patients had been treated with both agents. IL-1 inhibitors were employed in 38 different indications (37 with ANA, 16 with CAN). Off-label use was more frequent for ANA than CAN (p < 0.0001). ANA was employed as first-line biologic approach in 323 (76.7%) cases, while CAN in 37 cases (35.2%). IL-1 inhibitors were associated with corticosteroids in 285 (54.18%) courses and disease modifying anti-rheumatic drugs (DMARDs) in 156 (29.65%). ANA dosage ranged from 30 to 200 mg/day (or 1.0-2.0 mg/kg/day) among adults and 2-4 mg/kg/day among children; regarding CAN, the most frequently used posologies were 150mg every 8 weeks, 150mg every 4 weeks and 150mg every 6 weeks. The frequency of failure was higher among patients treated with ANA at a dosage of 100 mg/day than those treated with 2 mg/kg/day (p = 0.03). Seventy-six patients (14.4%) reported an adverse event (AE) and 10 (1.9%) a severe AE. AEs occurred more frequently after the age of 65 compared to both children and patients aged between 16 and 65 (p = 0.003 and p = 0.03, respectively). Conclusions: IL-1 inhibitors are mostly used off-label, especially ANA, during adulthood. The high frequency of good clinical responses suggests that IL-1 inhibitors are used with awareness of pathogenetic mechanisms; adult healthcare physicians generally employ standard dosages, while pediatricians are more prone in using a weight-based posology. Dose adjustments and switching between different agents showed to be effective treatment strategies. Our data confirm the good safety profile of IL-1 inhibitors.
- Published
- 2016
30. Presentation and progression of MPO-ANCA interstitial lung disease.
- Author
-
Salvati L, Palterer B, Lazzeri E, Vivarelli E, Amendola M, Allinovi M, Caroti L, Mazzoni A, Lasagni L, Emmi G, Cavigli E, Del Carria M, Di Pietro L, Scavone M, Cammelli D, Lavorini F, Tomassetti S, Rosi E, and Parronchi P
- Abstract
The association between MPO-ANCA-associated vasculitis (AAV) and interstitial lung disease (ILD) has been well established. Pulmonary fibrosis may coexist with, follow, or even precede the diagnosis of AAV, and its presence adversely affects the prognosis. The optimal approach to investigating ANCA in patients with ILD remains a subject of ongoing debate. Here we aim to describe presentation and progression of MPO-ANCA ILD. We conducted a retrospective evaluation of a cohort of individuals diagnosed with MPO-ANCA ILD, with or without accompanying renal impairment, at the Immunology and Cell Therapy Unit, Careggi University Hospital, Florence, Italy, between June 2016 and June 2022. Clinical records, imaging studies, pathologic examinations, and laboratory test results were collected. Among the 14 patients identified with MPO-ANCA ILD, we observed a significant association between MPO-ANCA titers assessed at the time of ILD diagnosis and renal involvement. Renal impairment in these cases often manifested as subclinical or slowly progressive kidney damage. Interestingly, complement C3 deposits were consistently found in all renal biopsy specimens, thereby suggesting the potential for novel therapeutic targets in managing renal complications associated with MPO-ANCA ILD. The presentation of MPO-ANCA vasculitis as ILD can be the first and only clinical manifestation. MPO-ANCA levels at ILD diagnosis could warn on the progression to renal involvement in patients with MPO-ANCA ILD, hence caution is needed because renal disease can be subclinical or smoldering., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
31. Anti-protein arginine deiminase antibodies are distinctly associated with joint and lung involvement in rheumatoid arthritis.
- Author
-
Palterer B, Vitiello G, Del Carria M, D'Onofrio B, Martinez-Prat L, Mahler M, Cammelli D, and Parronchi P
- Subjects
- Humans, Protein-Arginine Deiminases, Retrospective Studies, Protein-Arginine Deiminase Type 4, Autoantibodies, Lung, Immunoglobulin G, Arthritis, Rheumatoid complications, Lung Diseases, Interstitial
- Abstract
Objectives: RA is a chronic inflammatory disease in which possible interstitial lung disease (ILD) is an extra-articular manifestation that carries significant morbidity and mortality. RF and ACPA are included in the RA classification criteria but prognostic and diagnostic biomarkers for disease endotyping and RA-ILD are lacking. Anti-protein arginine deiminase antibodies (anti-PAD) are a novel class of autoantibodies identified in RA. This study aimed to assess clinical features, ACPA and anti-PAD antibodies in RA patients with articular involvement and ILD., Methods: We retrospectively collected joint erosions, space narrowing, clinical features and lung involvement of a cohort of 71 patients fulfilling the 2010 ACR/EULAR RA classification criteria. Serum samples from these patients were tested for ACPA IgG (QUANTA Flash CCP3), and anti-PAD3 and anti-PAD4 IgG, measured with novel assays based on a particle-based multi-analyte technology (PMAT)., Results: Anti-PAD4 antibodies were significantly associated with radiographic injury (P = 0.027) and erosions (P = 0.02). Similarly, ACPA levels were associated with erosive disease (P = 0.014). Anti-PAD3/4 double-positive patients displayed more joint erosions than patients with anti-PAD4 antibodies only or negative for both (P = 0.014 and P = 0.037, respectively). RA-ILD (15.5%, 11/71 patients) was associated with older age (P < 0.001), shorter disease duration (P = 0.045) and less erosive disease (P = 0.0063). ACPA were elevated in RA-ILD, while anti-PAD4 were negatively associated (P = 0.043)., Conclusion: Anti-PAD4 and anti-PAD3 antibodies identify RA patients with higher radiographic injury and bone erosions. In our cohort, ILD is associated with lower radiographic and erosive damage, as well as low levels of anti-PAD4 antibodies., (© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
32. Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study.
- Author
-
Quartuccio L, Isola M, Bruno D, Treppo E, Gigante L, Angelotti F, Capecchi R, Vitiello G, Cavallaro E, Tavoni A, Bosello SL, Cammelli D, De Vita S, and Gremese E
- Abstract
Objective: Glucocorticoids (GC) are associated with side effects in giant cell arteritis (GCA). Immunosuppressive therapies (ITs) have given conflicting results in GCA, regarding GC sparing effect. Primary endpoint is to evaluate whether very early introduction of ITs in GCA minimize the rate of GC-induced adverse events, in terms of infections, new onset systemic arterial hypertension, GC-induced diabetes and osteoporotic fractures., Methods: A multicenter retrospective case-control study included 165 patients. One group included 114 patients who were treated with at least one IT given at diagnosis or within 3 months from the start of GC. A second group included 51 GCA who received only GC or an IT more than 3 months later., Results: The most frequently used ITs were: methotrexate (138 patients), cyclophosphamide (48 patients) and tocilizumab (27 patients). No difference was observed as concerns the follow-up time between groups [48.5 (IQR 26-72) vs 40 (IQR 24-69), p = 0.3)]. The first group showed a significantly lower incidence of steroid-induced diabetes (8/114, 7% vs 12/51, 23.5%; p = 0.003) and no differences for the rate of infections (p = 0.64). The group was also exposed to lower doses of GC at first (p < 0.0001) and third (p < 0.0001, rank-sum test) month. Forty-four patients in the first group (38.6%) compared with 34 in the second one (66.7%) experienced at least one relapse (p = 0.001)., Conclusion: Very early introduction of IT in GCA lowered the incidence of steroid-induced diabetes, possibly due to the lower doses of GC in the first three months. Relapse rate was even lower., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2020 The Author(s).)
- Published
- 2020
- Full Text
- View/download PDF
33. Correction to: "When should primary angiitis of the central nervous system (PACNS) be suspected?": literature review and proposal of a preliminary screening algorithm.
- Author
-
Sarti C, Picchioni A, Telese R, Pasi M, Failli Y, Pracucci G, Cammelli D, and Inzitari D
- Abstract
The above article was published online with inverted given and family names. The correct presentation has been corrected above. The original article has been corrected.
- Published
- 2020
- Full Text
- View/download PDF
34. "When should primary angiitis of the central nervous system (PACNS) be suspected?": literature review and proposal of a preliminary screening algorithm.
- Author
-
Sarti C, Picchioni A, Telese R, Pasi M, Failli Y, Pracucci G, Cammelli D, and Inzitari D
- Subjects
- Algorithms, Humans, Magnetic Resonance Angiography, Neuroimaging, Vasculitis, Central Nervous System diagnostic imaging
- Abstract
Background: Primary angiitis of the CNS (PACNS) is a process causing variously combined neurological disturbances. Its rarity and kaleidoscopic presentation make it difficult to diagnose and even to suspect., Objective: (1) To provide an up-to-date review on PACNS and (2) to create a preliminary screening algorithm based on clinical and radiological first-level data, useful to suspect PACNS and guide further investigations., Methods: Review of PUBMED case series on PACNS, published from 2002 to 2017, collection of frequencies of clinical and neuroimaging features and calculation of median values. Classification of features as "major" or "minor" if frequency was higher or lower than median value. Combination of features in sets of criteria represented by all possible combinations of major and minor clinical and neuroradiological features. Application of criteria to published PACNS case reports and selection of the ones best identifying patients with definite PACNS., Results: We reviewed 24 case series. "Major" clinical features were headache, stroke, cognitive impairment, focal neurological deficits; "minor" were seizures, altered consciousness, psychiatric disorders. "Major" neuroradiological features were multiple parenchymal lesions, parenchymal/meningeal contrast enhancement, magnetic resonance angiography vessel abnormalities, vessel wall enhancement; "minor" were parenchymal/subarachnoid hemorrhage, single parenchymal lesion. The selected sets of criteria able to identify all PACNS patients were (1) one clinical (major/minor) + one major neuroradiological feature; and (2) Two clinical (≥ 1 major) + one minor neuroradiological feature., Conclusion: Our review provides a detailed clinical/neuroradiological picture of PACNS. The proposed algorithm should be regarded as a preliminary screening tool to move the first steps towards PACNS diagnosis that needs validation.
- Published
- 2020
- Full Text
- View/download PDF
35. Efficacy and Safety of High-Dose Immunoglobulin-Based Regimen in Statin-Associated Autoimmune Myopathy: A Multi-Center and Multi-Disciplinary Retrospective Study.
- Author
-
Treppo E, Infantino M, Benucci M, Ravagnani V, Palterer B, Fabris M, Tomietto P, Manfredi M, Giudizi MG, Ligobbi F, Cammelli D, Grandis M, Parronchi P, De Vita S, and Quartuccio L
- Abstract
Statin-associated autoimmune myopathy is a rare muscle disorder, characterized by autoantibodies against HMGCR. The anti-HMGCR myopathy persists after statin, and often requires immunosuppressive therapy. However, there is not a standardized therapeutic approach. The purpose of this study is to report the effectiveness of the immunosuppressive treatment employed in a multi-center and multi-disciplinary cohort of patients affected by anti-HMGCR myopathy, in which an immunoglobulin (IVIG)-based treatment strategy was applied. We collected 16 consecutive patients with a diagnosis of anti-HMGCR myopathy, between 2012 and 2019, and recorded data on clinical and laboratory presentation (i.e., muscle strength, serum CK levels, and anti-HMGCR antibody titer) and treatment strategies. Our results highlight the safety and efficacy of an induction therapy combining IVIG with GCs and/or methotrexate to achieve persistent remission of the disease and steroid-free maintenance. Under IVIG-based regimens, clinical improvement and CK normalization occurred in more than two thirds of patients by six months. Relapse rate was low (3/16) and 2/3 relapses occurred after treatment suspension. Nearly 90% of the patients who successfully discontinued GCs were treated with a triple immunosuppressive regimen. In conclusion, an IVIG-based regimen, which particularly includes high-dose immunoglobulin, GCs and methotrexate, can provide a fast remission achievement with GC saving.
- Published
- 2020
- Full Text
- View/download PDF
36. Into the Heart of Polymyalgia Rheumatica.
- Author
-
Vitiello G, Verrone GB, Stefàno PL, Fayaz Torshizi M, Castellani S, and Cammelli D
- Subjects
- Diagnosis, Differential, Humans, Giant Cell Arteritis diagnosis, Polymyalgia Rheumatica diagnosis, Polymyalgia Rheumatica drug therapy
- Published
- 2020
- Full Text
- View/download PDF
37. Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes.
- Author
-
Vitale A, Cavalli G, Ruscitti P, Sota J, Colafrancesco S, Priori R, Valesini G, Argolini LM, Baldissera E, Bartoloni E, Cammelli D, Canestrari G, Cavallaro E, Massaro MG, Cipriani P, De Marchi G, De Vita S, Emmi G, Frassi M, Gerli R, Gremese E, Iannone F, Fornaro M, Paladini A, Lopalco G, Manna R, Mathieu A, Montecucco C, Mosca M, Piazza I, Piga M, Pontikaki I, Romano M, Rossi S, Rossini M, Silvestri E, Stagnaro C, Talarico R, Frediani B, Tincani A, Viapiana O, Vitiello G, Galozzi P, Sfriso P, Gaggiano C, Grosso S, Rigante D, Dagna L, Giacomelli R, and Cantarini L
- Abstract
Background: Aim of this study was to search for any difference in the outcome of patients with adult onset Still's disease (AOSD) treated with anakinra (ANK) in relation with the interval between disease onset and the start of anti-interleukin(IL)-1 treatment and according with the different lines of ANK treatment. Patients and Methods: One hundred and forty-one AOSD patients treated with ANK have been retrospectively assessed. Statistically significant differences ( p < 0.05) were analyzed in the frequency of ANK effectiveness, primary or secondary inefficacy to ANK and rate of resolution of clinical and laboratory AOSD manifestations after 3, 6, and 12 months since ANK treatment according with different lines of treatment and different times between AOSD onset and start of ANK. Results: No significant differences were identified in the ANK effectiveness and frequency of primary or secondary inefficacy for patients starting ANK within 6 months ( p = 0.19, p = 0.14, and p = 0.81, respectively) or 12 months ( p = 0.37, p = 0.23, and p = 0.81, respectively) since AOSD onset compared with patients starting ANK thereafter; no significant differences were identified in ANK effectiveness and primary or secondary inefficacy according with different lines of ANK treatment ( p = 0.06, p = 0.19, and p = 0.13, respectively). Patients starting ANK within 6 and 12 months since AOSD onset showed a significantly quicker decrease of erythrocyte sedimentation rate and C-reactive protein than observed among patients undergoing ANK treatment after 6 and 12 months. The number of swollen joints at the 3 month follow-up visit was significantly lower among patients undergoing ANK within 6 months since AOSD onset ( p = 0.01), while no significance was identified at the 6 and 12 month assessments ( p = 0.23 and p = 0.45, respectively). At the 3 and 6 month visits, the number of swollen joints was significantly higher among patients previously treated with conventional and biological disease modifying anti-rheumatic drugs (DMARDs) compared with those formerly treated only with conventional DMARDs ( p < 0.017). Conclusions: Clinical and therapeutic outcomes are substantially independent of how early ANK treatment is started in AOSD patients. However, a faster ANK effectiveness in controlling systemic inflammation and resolving articular manifestations may be observed in patients benefiting from IL-1 inhibition as soon as after disease onset., (Copyright © 2020 Vitale, Cavalli, Ruscitti, Sota, Colafrancesco, Priori, Valesini, Argolini, Baldissera, Bartoloni, Cammelli, Canestrari, Cavallaro, Massaro, Cipriani, De Marchi, De Vita, Emmi, Frassi, Gerli, Gremese, Iannone, Fornaro, Paladini, Lopalco, Manna, Mathieu, Montecucco, Mosca, Piazza, Piga, Pontikaki, Romano, Rossi, Rossini, Silvestri, Stagnaro, Talarico, Frediani, Tincani, Viapiana, Vitiello, Galozzi, Sfriso, Gaggiano, Grosso, Rigante, Dagna, Giacomelli and Cantarini.)
- Published
- 2020
- Full Text
- View/download PDF
38. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course.
- Author
-
Cavagna L, Trallero-Araguás E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, Zanframundo G, Morandi V, Meyer A, Pereira da Silva JA, Matos Costa CJ, Molberg O, Andersson H, Codullo V, Mosca M, Barsotti S, Neri R, Scirè C, Govoni M, Furini F, Lopez-Longo FJ, Martinez-Barrio J, Schneider U, Lorenz HM, Doria A, Ghirardello A, Ortego-Centeno N, Confalonieri M, Tomietto P, Pipitone N, Rodriguez Cambron AB, Blázquez Cañamero MÁ, Voll RE, Wendel S, Scarpato S, Maurier F, Limonta M, Colombelli P, Giannini M, Geny B, Arrigoni E, Bravi E, Migliorini P, Mathieu A, Piga M, Drott U, Delbrueck C, Bauhammer J, Cagnotto G, Vancheri C, Sambataro G, De Langhe E, Sainaghi PP, Monti C, Gigli Berzolari F, Romano M, Bonella F, Specker C, Schwarting A, Villa Blanco I, Selmi C, Ceribelli A, Nuno L, Mera-Varela A, Perez Gomez N, Fusaro E, Parisi S, Sinigaglia L, Del Papa N, Benucci M, Cimmino MA, Riccieri V, Conti F, Sebastiani GD, Iuliano A, Emmi G, Cammelli D, Sebastiani M, Manfredi A, Bachiller-Corral J, Sifuentes Giraldo WA, Paolazzi G, Saketkoo LA, Giorgi R, Salaffi F, Cifrian J, Caporali R, Locatelli F, Marchioni E, Pesci A, Dei G, Pozzi MR, Claudia L, Distler J, Knitza J, Schett G, Iannone F, Fornaro M, Franceschini F, Quartuccio L, Gerli R, Bartoloni E, Bellando Randone S, Zampogna G, Gonzalez Perez MI, Mejia M, Vicente E, Triantafyllias K, Lopez-Mejias R, Matucci-Cerinic M, Selva-O'Callaghan A, Castañeda S, Montecucco C, and Gonzalez-Gay MA
- Abstract
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group's cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The "ex-novo" occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies' positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.
- Published
- 2019
- Full Text
- View/download PDF
39. Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease.
- Author
-
Sota J, Rigante D, Ruscitti P, Insalaco A, Sfriso P, de Vita S, Cimaz R, Lopalco G, Emmi G, La Torre F, Fabiani C, Olivieri AN, Cattalini M, Cammelli D, Gallizzi R, Alessio M, Manna R, Viapiana O, Frassi M, Pardeo M, Maier A, Salvarani C, Talarico R, Mosca M, Colafrancesco S, Priori R, Maggio MC, Gaggiano C, Grosso S, De Benedetti F, Vitale A, Giacomelli R, and Cantarini L
- Abstract
Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Herein we report on the effectiveness of anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and Methods: This is a multicenter study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48-, and 60-month of follow-up was 74.3%, 62.9%, 49.4%, and 49.4%, respectively, without any significant differences between sJIA and AOSD patients ( p = 0.164), and between patients treated in monotherapy compared with the subgroup coadministered with conventional disease-modifying antirheumatic drugs (cDMARDs) ( p = 0.473). On the other hand, a significant difference in DRR was found between biologic-naïve patients and those previously treated with biotechnologic drugs ( p = 0.009), which persisted even after adjustment for pathology ( p = 0.013). In the regression analysis, patients experiencing adverse events (AEs) {hazards ratio (HR) = 3.029 [confidence interval (CI) 1.750-5.242], p < 0.0001} and those previously treated with other biologic agents [HR = 1.818 (CI 1.007-3.282), p = 0.047] were associated with a higher HR of ANA discontinuation. The median treatment delay was significantly higher among patients discontinuing ANA ( p < 0.0001). Significant corticosteroid-sparing ( p = 0.033) and cDMARD-sparing effects ( p < 0.0001) were also recorded. Less than one-third of our cohort developed AEs, and 85% were deemed mild in nature, with 70% of them involving the skin. Conclusions: Our findings display an overall excellent DRR of ANA on the long run for both sJIA and AOSD, that may be further optimized by closely monitoring patient's safety issues and employing this IL-1 inhibitor as a first-line biologic as early as possible. Moreover, ANA allowed a significant drug-sparing effect and showed an overall good safety profile.
- Published
- 2019
- Full Text
- View/download PDF
40. Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response.
- Author
-
Vitale A, Cavalli G, Colafrancesco S, Priori R, Valesini G, Argolini LM, Baldissera E, Bartoloni E, Cammelli D, Canestrari G, Sota J, Cavallaro E, Massaro MG, Ruscitti P, Cipriani P, De Marchi G, De Vita S, Emmi G, Ferraccioli G, Frassi M, Gerli R, Gremese E, Iannone F, Lapadula G, Lopalco G, Manna R, Mathieu A, Montecucco C, Mosca M, Piazza I, Piga M, Pontikaki I, Romano M, Rossi S, Rossini M, Silvestri E, Stagnaro C, Talarico R, Tincani A, Viapiana O, Vitiello G, Galozzi P, Sfriso P, Gaggiano C, Rigante D, Dagna L, Giacomelli R, and Cantarini L
- Abstract
Background: Anakinra (ANA) is an effective treatment choice in patients with adult onset Still's disease (AOSD). Variables affecting treatment survival include loss of efficacy or adverse events, but also the decision to discontinue treatment after long-term clinical remission. Objectives: Aims of this study were: (i) to assess the drug retention rate (DRR) of ANA during a long-term follow-up looking for any difference related to the line of biologic treatment, the concomitant use of conventional disease modifying anti-rheumatic drugs (cDMARDs) and the different type of AOSD (systemic versus chronic articular); (ii) to identify predictive factors of lack of efficacy, loss of efficacy, and ANA withdrawal owing to long-term remission. Methods: AOSD patients classified according with Yamaguchi criteria and treated with ANA were retrospectively enrolled in 18 Italian tertiary Centers. Demographic, laboratory, clinical and therapeutic data related to the start of ANA ( baseline ), the 3-month assessment and the last follow-up visit while on ANA treatment were retrospectively collected and statistically analyzed. Results: One hundred and forty-one AOSD patients (48 males, 93 females) treated with ANA for a mean period of 35.96 ± 36.05 months were enrolled. The overall DRR of ANA was 44.6 and 30.5% at the 60- and 120-month assessments, respectively, with no significant differences between: (i) biologic naïve patients and those previously treated with other biologics (log-rank p = 0.97); (ii) monotherapy and concomitant use of cDMARDs (log-rank p = 0.45); (iii) systemic and chronic articular types of AOSD (log-rank p = 0.67). No variables collected at baseline could predict primary inefficacy, while the number of swollen joints at baseline was significantly associated with secondary inefficacy ( p = 0.01, OR = 1.194, C.I. 1.043-1.367). The typical AOSD skin rash was negatively related with ANA withdrawal owing to long-term remission ( p = 0.03, OR = 0.224, C.I. 0.058-0.863). Conclusion: Long-term DRR of ANA has been found excellent and is not affected by different lines of biologic treatment, concomitant use of cDMARDs, or type of AOSD. The risk of losing ANA efficacy increases along with the number of swollen joints at the start of therapy, while the typical skin rash is a negative predictor of ANA withdrawal related to sustained remission.
- Published
- 2019
- Full Text
- View/download PDF
41. Preeclampsia in pregnancies complicated by systemic lupus erythematosus (SLE) nephritis: prophylactic treatment with multidisciplinary approach are important keys to prevent adverse obstetric outcomes.
- Author
-
Mecacci F, Simeone S, Cirami CL, Cozzolino M, Serena C, Rambaldi MP, Gallo P, Emmi L, Cammelli D, Mello G, and Matucci Cerinic M
- Subjects
- Adult, Antibodies, Antiphospholipid blood, Aspirin administration & dosage, Case-Control Studies, Creatinine blood, Female, Fibrinolytic Agents administration & dosage, Heparin, Low-Molecular-Weight administration & dosage, Humans, Lupus Nephritis drug therapy, Pregnancy, Pregnancy Outcome epidemiology, Retrospective Studies, Risk Factors, Ultrasonography, Prenatal, Uterine Artery diagnostic imaging, Lupus Nephritis complications, Pre-Eclampsia prevention & control
- Abstract
Introduction: Systemic lupus erythematosus (SLE) commonly affects women of childbearing age. Hypertension, antiphospholipid syndrome, and lupus nephritis are risk factors for adverse maternal/fetal outcome. The aim of this retrospective cohort study is to compare pregnancy outcomes in patients with and without SLE nephritis, using a multidisciplinary approach and a broad prophylaxis protocol., Materials and Methods: Data were collected from 86 pregnancies complicated by SLE. Twenty-seven women with nephropathy before pregnancy stated as the study group and 59 formed the control group. Each group received a prophylactic treatment based on their clinical characteristics. Results were expressed as mean ± SD, percentage and χ
2 -test (significant values when p < .05)., Results: The prophylactic treatment (60.4% of the patients) significantly controlled the complications related to some risk factors, such as antiphospholipid antibodies (aPL) and nephritis. Preeclampsia occurred in 14.8% of patients. Patients with pregestational hypertension showed a 2.75 odds ratio of adverse events when compared to the group without chronic hypertension. The presence of proteinuria was associated with a risk of preeclampsia 2.45 times greater, as well as serum creatinine >1.2 mg/dL, which was related to a risk 1.25 times higher than the risk observed in patients with serum creatinine <1.2 mg/dL. A 6-month inactive disease was associated with a better outcome. A value of Estimated Glomerular Filtration Rate (eGFR) < 90 mL/min/1.73 m2 resulted in a 18.73 times greater risk of preeclampsia, intrauterine growth restriction (IUGR), and preterm delivery., Discussion: A multidisciplinary approach in a tertiary care center and a broad prophylactic treatment protocol to patients affected by SLE and complicated by nephritis may definitively foster a successful pregnancy.- Published
- 2019
- Full Text
- View/download PDF
42. T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis.
- Author
-
Pratesi S, Nencini F, Grosso F, Dies L, Bormioli S, Cammelli D, Maggi E, Matucci A, and Vultaggio A
- Subjects
- Adult, Aged, Antirheumatic Agents administration & dosage, Arthritis, Psoriatic drug therapy, Arthritis, Psoriatic immunology, Arthritis, Rheumatoid blood, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid immunology, Drug Hypersensitivity blood, Drug Hypersensitivity diagnosis, Drug Hypersensitivity etiology, Female, Humans, Inflammatory Bowel Diseases blood, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases immunology, Infliximab administration & dosage, Infusions, Intravenous, Interferon-gamma immunology, Interferon-gamma metabolism, Interleukin-10 immunology, Interleukin-10 metabolism, Longitudinal Studies, Male, Middle Aged, Spondylarthritis blood, Spondylarthritis drug therapy, Spondylarthritis immunology, T-Lymphocytes immunology, T-Lymphocytes metabolism, Treatment Outcome, Antirheumatic Agents adverse effects, Drug Hypersensitivity immunology, Infliximab adverse effects, Lymphocyte Activation drug effects, T-Lymphocytes drug effects
- Abstract
This study aimed to evaluate the proportion of infliximab (IFX)-exposed patients exhibiting cellular response to the drug in a longitudinal way and to establish whether it is predictive for anti-drug antibodies (ADA) development. Seventeen patients suffering from immuno-mediated disorders were enrolled. Blood was sampled at baseline and before each of the first eight infusions of IFX. The proliferation of PBMCs to 15-mer peptides covering VH/VL frames of IFX was assessed as well as transcription factors and cytokines mRNA expression of memory T cells in IFX-stimulated PBMCs. The number of peptides recognized by T cells after four infusions was higher than those recognized by the same patients before treatment. IFX-stimulated PBMCs from more than 90% of patients were able to express the main regulators and adaptive cytokines of memory T cells. While IFN-γ mRNAs increased after the first infusion and declined during the subsequent ones, IL-10 mRNA was upregulated throughout the treatment. IL-10 was functionally active because its neutralization improved IFN-γ and IL-13 mRNA expression in vitro . The IL-10/IFN-γ ratio was shown to be lower in patients who developed ADAs solely at the early infusions. IL-10 production consistently preceded or paralleled the IFN-γ onset in ADA- patients, while it was not produced or followed IFN-γ onset in ADA+ patients. In conclusion, this study provides evidence that the majority of exposed patients undergo a cellular response to IFX with the upregulation of IL-10. The development of ADA is associated with the early impairment of IL-10 and low levels of the IL-10/IFN-γ ratio.
- Published
- 2019
- Full Text
- View/download PDF
43. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders.
- Author
-
Nencini F, Vultaggio A, Pratesi S, Cammelli D, Milla M, Fiori G, Bagnoli S, Prignano F, Romagnani S, Maggi E, and Matucci A
- Subjects
- Adult, Aged, Antirheumatic Agents blood, Drug Hypersensitivity diagnosis, Drug Monitoring, Female, Humans, Immune System Diseases diagnosis, Immunity, Humoral, Infliximab blood, Male, Middle Aged, Prognosis, Treatment Outcome, Antirheumatic Agents immunology, Drug Hypersensitivity immunology, Immune System Diseases immunology, Immunoglobulin E blood, Infliximab immunology
- Abstract
Background: Hypersensitivity reactions (HRs) and loss of response (LOR) to infliximab (IFX) are related to drug immunogenicity characterized by antidrug antibodies (ADAs)., Objective: To analyze the timing of ADA appearance and its relationship with drug levels and clinical outcomes in IFX-treated patients with different diseases., Methods: Samples were longitudinally collected before each infusion from 91 IFX-treated patients and were assayed for ADA and drug levels by enzyme-linked immunosorbent assay and for IgE by ImmunoCAP system. Clinical data regarding efficacy and safety of therapy were also monitored., Results: The ADA onset occured quite early, irrespective of the type of disease, during the first year and more frequently and earlier during the second cycle of therapy. Patients with HR were more frequently ADA-positive and with higher ADA titers compared with other patient groups. ADA onset tends to precede HRs and LOR; all HRs that occur after a period of drug interruption are preceded by ADA development. Before ADA detection, a progressive decline in IFX levels until a complete disappearance was observed. The ADA titer was maintained for years both in patients with ongoing therapy and in those who interrupted it. IgE ADAs are more frequently developed in patients with higher ADA levels and earlier ADA onset, but their rate of negativization is faster., Conclusion: The present data suggest that most IFX-exposed patients develop ADAs within the first year of treatment irrespective of disease type. The clinical outcome to the treatment is preceded by ADA development, which in turn is associated with the reduction in drug serum levels. Both ADA evaluation and therapeutic drug monitoring may have a relevant impact on clinical practice, giving new insights to predict LOR and HRs., (Copyright © 2018 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
44. Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study.
- Author
-
Vitiello G, Orsi Battaglini C, Carli G, Radice A, Matucci A, Vultaggio A, Olianti C, Parronchi P, Maggi E, and Cammelli D
- Subjects
- Aged, Aged, 80 and over, Female, Fluorodeoxyglucose F18, Giant Cell Arteritis diagnostic imaging, Glucocorticoids therapeutic use, Humans, Male, Middle Aged, Positron-Emission Tomography, Retrospective Studies, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Giant Cell Arteritis drug therapy
- Abstract
This study aims to evaluate (1) the efficacy and safety of tocilizumab (TCZ) as a steroid-sparing agent in patients with giant cell arteritis (GCA) and (2) the usefulness of
18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) in the follow-up and to detect disease activity. We retrospectively evaluated 12 patients with GCA treated with TCZ (8 mg/kg/mo). Pre- and posttherapy data about clinical signs and symptoms, laboratory results, FDG-PET imaging study, and the mean glucocorticoid (GC) dose were used to assess disease activity. Tocilizumab achieved complete disease remission in all patients. Mean FDG-PET-detected standard uptake value decreased from 2.05 ± 0.64 to 1.78 ± 0.45 ( P = .005). In 2 patients in whom temporal arteries color Doppler sonography examination was consistent with temporal arteritis, the hypoechoic halo disappeared after TCZ treatment. Mean GC dose was tapered from 26.6 ± 13.4 mg/d to 3.3 ± 3.1 mg/d ( P < .0001). One-half of the patients discontinued GC therapy. Three patients experienced severe adverse reactions and had to stop TCZ therapy. In accordance with previous reports, TCZ is an effective steroid-sparing agent for GCA, although careful monitoring of adverse drug reactions is needed.18 F-fluorodeoxyglucose positron emission tomography could be used to monitor disease activity in TCZ-treated patients, but prospective studies are needed to confirm these data.- Published
- 2018
- Full Text
- View/download PDF
45. Bench to bedside review of myositis autoantibodies.
- Author
-
Palterer B, Vitiello G, Carraresi A, Giudizi MG, Cammelli D, and Parronchi P
- Abstract
Idiopathic inflammatory myopathies represent a heterogeneous group of autoimmune diseases with systemic involvement. Even though numerous specific autoantibodies have been recognized, they have not been included, with the only exception of anti-Jo-1, into the 2017 Classification Criteria, thus perpetuating a clinical-serologic gap. The lack of homogeneous grouping based on the antibody profile deeply impacts the diagnostic approach, therapeutic choices and prognostic stratification of these patients. This review is intended to highlight the comprehensive scenario regarding myositis-related autoantibodies, from the molecular characterization and biological significance to target antigens, from the detection tools, with a special focus on immunofluorescence patterns on HEp-2 cells, to their relative prevalence and ethnic diversity, from the clinical presentation to prognosis. If, on the one hand, a notable body of literature is present, on the other data are fragmented, retrospectively based and collected from small case series, so that they do not sufficiently support the decision-making process (i.e. therapeutic approach) into the clinics.
- Published
- 2018
- Full Text
- View/download PDF
46. Systemic Vasculopathy in a Patient With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome.
- Author
-
Cammelli D, Vitiello G, Troilo A, Comin CE, and Cantarini L
- Subjects
- Adult, Diagnosis, Differential, Fatal Outcome, Female, Humans, Liver blood supply, Liver pathology, Lung blood supply, Lung pathology, Mutation, Pericardium pathology, Psoas Muscles blood supply, Psoas Muscles pathology, Arterioles pathology, Familial Mediterranean Fever diagnosis, Familial Mediterranean Fever genetics, Familial Mediterranean Fever physiopathology, Familial Mediterranean Fever therapy, Patient Care Management methods, Receptors, Tumor Necrosis Factor, Type I genetics, Vascular Diseases diagnosis, Vascular Diseases etiology, Vascular Diseases physiopathology, Vascular Diseases therapy
- Published
- 2017
- Full Text
- View/download PDF
47. Large-vessel Involvement and Varicella Zoster Virus Vasculopathy in Giant Cell Arteritis-related Stroke: Something to Keep an Eye On.
- Author
-
Vitiello G and Cammelli D
- Subjects
- Case-Control Studies, Herpesvirus 3, Human, Humans, Retrospective Studies, Giant Cell Arteritis, Herpes Zoster, Stroke
- Published
- 2017
- Full Text
- View/download PDF
48. Sustained tocilizumab-induced hypofibrinogenemia and thrombocytopenia. Comment on: "Tocilizumab-induced hypofibrinogenemia: A report of 7 cases" by Martis et al., Joint Bone Spine 2016, doi: 10.1016/j.jbspin.2016.04.008.
- Author
-
Vitiello G, Orsi Battaglini C, Radice A, Carli G, Micheli S, and Cammelli D
- Subjects
- Humans, Receptors, Interleukin-6, Antibodies, Monoclonal, Humanized, Thrombocytopenia
- Published
- 2017
- Full Text
- View/download PDF
49. IL-10-Producing Infliximab-Specific T Cells Regulate the Antidrug T Cell Response in Exposed Patients.
- Author
-
Vultaggio A, Nencini F, Pratesi S, Cammelli D, Totaro M, Romagnani S, Maggi E, and Matucci A
- Subjects
- Adult, Coculture Techniques, Cytokines biosynthesis, Cytokines immunology, Dendritic Cells drug effects, Dendritic Cells immunology, Female, Humans, Immune System Diseases drug therapy, Immune System Diseases immunology, Immunologic Memory drug effects, Infliximab therapeutic use, Interleukin-10 blood, Interleukin-10 genetics, Interleukin-10 immunology, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear immunology, Lymphocyte Activation drug effects, Male, Middle Aged, Receptors, Virus genetics, Receptors, Virus immunology, T-Lymphocytes metabolism, Infliximab immunology, Infliximab pharmacology, Interleukin-10 biosynthesis, T-Lymphocytes drug effects, T-Lymphocytes immunology
- Abstract
Infliximab (IFX) is a chimeric mAb that can lead to the appearance of anti-drug Abs. Recent research has identified the presence of circulating IFX-specific T cells in treated patients. The aim of the study was to analyze the functional characteristics of IFX-specific T cells, in particular their capability to produce biologically active regulatory cytokines. Drug-stimulated PBMCs or coculture systems were used to detect memory T cells in treated patients. The cytokines produced by IFX-specific T cells, T cell lines, and T cell clones were evaluated at the mRNA and protein levels. Drug infusion induced an increase in IL-10 serum levels in vivo, whereas other cytokines were unchanged. IL-10 mRNA was higher in IFX-stimulated PBMCs from treated patients compared with untreated patients. When analyzed longitudinally, an early IL-10 mRNA expression was observed. HLA class II-restricted IL-10 production by drug-specific T cells from exposed patients was observed in different experimental settings, such as a coculture system, sorted CD154
+ T cells, IFX peptide-stimulated PBMCs, and IFX-specific T cell clones. Finally, IL-10-producing drug-specific T cell clones downregulated the response of autologous effector T cells to IFX. Overall, these findings identify IFX-specific T cells as a source of biologically active IL-10 and suggest interference by IL-10-producing cells in the detection of drug-specific T cells., (Copyright © 2017 by The American Association of Immunologists, Inc.)- Published
- 2017
- Full Text
- View/download PDF
50. Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study.
- Author
-
Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, Cammelli D, Canestrari G, Cantarini L, Cavallaro E, Cavalli G, Cerrito L, Cipriani P, Dagna L, Marchi G, Vita S, Emmi G, Ferraccioli G, Frassi M, Galeazzi M, Gerli R, Giacomelli R, Gremese E, Iannone F, Lapadula G, Lopalco G, Manna R, Mathieu A, Montecucco C, Mosca M, Piazza I, Piga M, Pontikaki I, Romano M, Rossi S, Rossini M, Ruscitti P, Silvestri E, Stagnaro C, Talarico R, Tincani A, Viapiana O, Vitiello G, Fabris F, Bindoli S, Punzi L, Galozzi P, and Sfriso P
- Abstract
Background: Interleukin (IL)-1 plays a crucial role in the pathogenesis of Adult onset Still's disease (AOSD). Objectives: To evaluate the efficacy and safety of anakinra (ANA) and canakinumab (CAN) in a large group of AOSD patients. Methods: Data on clinical, serological features, and concomitant treatments were retrospectively collected at baseline and after 3, 6, and 12 months from AOSD patients (Yamaguchi criteria) referred by 18 Italian centers. Pouchot's score was used to evaluate disease severity. Results: One hundred forty patients were treated with ANA; 4 were subsequently switched to CAN after ANA failure. The systemic pattern of AOSD was identified in 104 (74.2%) of the ANA-treated and in 3 (75%) of the CAN-treated groups; the chronic-articular type of AOSD was identified in 48 (25.8%) of the ANA-treated and in 1 (25%) of the CAN-treated groups. Methotrexate (MTX) was the most frequent disease modifying anti-rheumatic drug (DMARD) used before beginning ANA or CAN [91/140 (75.8%), 2/4 (50%), respectively]. As a second-line biologic DMARD therapy in 29/140 (20.7%) of the patients, ANA was found effective in improving all clinical and serological manifestations ( p < 0.0001), and Pouchot's score was found to be significantly reduced at all time points ( p < 0.0001). No differences in treatment response were identified in the ANA-group when the patients were stratified according to age, sex, disease pattern or mono/combination therapy profile. ANA primary and secondary inefficacy at the 12-month time point was 15/140 (10.7%) and 11/140 (7.8%), respectively. Adverse events (AEs) [mainly represented by in situ (28/47, 59.5%) or diffuse (12/47, 25.5%) skin reactions and infections (7/47, 14.8%)] were the main causes for discontinuation. Pouchot's score and clinical and serological features were significantly ameliorated at all time points ( p < 0.0001) in the CAN-group, and no AEs were registered during CAN therapy. Treatment was suspended for loss of efficacy only in one case (1/4, 25%). Conclusion: This is the largest retrospective observational study evaluating the efficacy and safety of IL-1 inhibitors in AOSD patients. A good response was noted at 3 months after therapy onset in both the ANA- and CAN-groups. Skin reaction may nevertheless represent a non-negligible AE during ANA treatment.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.